6	TREANDA.xml:S1:4:1	O
ADVERSE	TREANDA.xml:S1:6:7	O
REACTIONS	TREANDA.xml:S1:14:9	O

The	TREANDA.xml:S1:27:3	O
following	TREANDA.xml:S1:31:9	O
serious	TREANDA.xml:S1:41:7	O
adverse	TREANDA.xml:S1:49:7	O
reactions	TREANDA.xml:S1:57:9	O
have	TREANDA.xml:S1:67:4	O
been	TREANDA.xml:S1:72:4	O
associated	TREANDA.xml:S1:77:10	O
with	TREANDA.xml:S1:88:4	O
TREANDA	TREANDA.xml:S1:93:7	O
in	TREANDA.xml:S1:101:2	O
clinical	TREANDA.xml:S1:104:8	O
trials	TREANDA.xml:S1:113:6	O
and	TREANDA.xml:S1:120:3	O
are	TREANDA.xml:S1:124:3	O
discussed	TREANDA.xml:S1:128:9	O
in	TREANDA.xml:S1:138:2	O
greater	TREANDA.xml:S1:141:7	O
detail	TREANDA.xml:S1:149:6	O
in	TREANDA.xml:S1:156:2	O
other	TREANDA.xml:S1:159:5	O
sections	TREANDA.xml:S1:165:8	O
of	TREANDA.xml:S1:174:2	O
the	TREANDA.xml:S1:177:3	O
label	TREANDA.xml:S1:181:5	O
.	TREANDA.xml:S1:186:1	O

Myelosuppression	TREANDA.xml:S1:197:16	B-AdverseReaction
[	TREANDA.xml:S1:214:1	O
see	TREANDA.xml:S1:215:3	O
Warnings	TREANDA.xml:S1:220:8	O
and	TREANDA.xml:S1:229:3	O
Precautions	TREANDA.xml:S1:233:11	O
(	TREANDA.xml:S1:246:1	O
5.1	TREANDA.xml:S1:249:3	O
)]	TREANDA.xml:S1:254:2	O

Infections	TREANDA.xml:S1:265:10	B-AdverseReaction
[	TREANDA.xml:S1:276:1	O
see	TREANDA.xml:S1:277:3	O
Warnings	TREANDA.xml:S1:282:8	O
and	TREANDA.xml:S1:291:3	O
Precautions	TREANDA.xml:S1:295:11	O
(	TREANDA.xml:S1:308:1	O
5.2	TREANDA.xml:S1:311:3	O
)]	TREANDA.xml:S1:316:2	O

Anaphylaxis	TREANDA.xml:S1:327:11	B-AdverseReaction
and	TREANDA.xml:S1:339:3	O
Infusion	TREANDA.xml:S1:343:8	B-AdverseReaction
Reactions	TREANDA.xml:S1:352:9	I-AdverseReaction
[	TREANDA.xml:S1:362:1	O
see	TREANDA.xml:S1:363:3	O
Warnings	TREANDA.xml:S1:368:8	O
and	TREANDA.xml:S1:377:3	O
Precautions	TREANDA.xml:S1:381:11	O
(	TREANDA.xml:S1:394:1	O
5.3	TREANDA.xml:S1:397:3	O
)]	TREANDA.xml:S1:402:2	O

Tumor	TREANDA.xml:S1:413:5	B-AdverseReaction
Lysis	TREANDA.xml:S1:419:5	I-AdverseReaction
Syndrome	TREANDA.xml:S1:425:8	I-AdverseReaction
[	TREANDA.xml:S1:434:1	O
see	TREANDA.xml:S1:435:3	O
Warnings	TREANDA.xml:S1:440:8	O
and	TREANDA.xml:S1:449:3	O
Precautions	TREANDA.xml:S1:453:11	O
(	TREANDA.xml:S1:466:1	O
5.4	TREANDA.xml:S1:469:3	O
)]	TREANDA.xml:S1:474:2	O

Skin	TREANDA.xml:S1:485:4	B-AdverseReaction
Reactions	TREANDA.xml:S1:490:9	I-AdverseReaction
[	TREANDA.xml:S1:500:1	O
see	TREANDA.xml:S1:501:3	O
Warnings	TREANDA.xml:S1:506:8	O
and	TREANDA.xml:S1:515:3	O
Precautions	TREANDA.xml:S1:519:11	O
(	TREANDA.xml:S1:532:1	O
5.5	TREANDA.xml:S1:535:3	O
)]	TREANDA.xml:S1:540:2	O

Other	TREANDA.xml:S1:551:5	O
Malignancies	TREANDA.xml:S1:557:12	B-AdverseReaction
[	TREANDA.xml:S1:570:1	O
see	TREANDA.xml:S1:571:3	O
Warnings	TREANDA.xml:S1:576:8	O
and	TREANDA.xml:S1:585:3	O
Precautions	TREANDA.xml:S1:589:11	O
(	TREANDA.xml:S1:602:1	O
5.6	TREANDA.xml:S1:605:3	O
)]	TREANDA.xml:S1:610:2	O

Extravasation	TREANDA.xml:S1:621:13	B-AdverseReaction
injury	TREANDA.xml:S1:635:6	I-AdverseReaction
[	TREANDA.xml:S1:642:1	O
see	TREANDA.xml:S1:643:3	O
Warnings	TREANDA.xml:S1:648:8	O
and	TREANDA.xml:S1:657:3	O
Precautions	TREANDA.xml:S1:661:11	O
(	TREANDA.xml:S1:673:1	O
5.7	TREANDA.xml:S1:674:3	O
)]	TREANDA.xml:S1:677:2	O

Most	TREANDA.xml:S1:702:4	O

common	TREANDA.xml:S1:707:6	O
non	TREANDA.xml:S1:714:3	O
-	TREANDA.xml:S1:717:1	O
hematologic	TREANDA.xml:S1:718:11	O
adverse	TREANDA.xml:S1:730:7	O
reactions	TREANDA.xml:S1:738:9	O
for	TREANDA.xml:S1:748:3	O
CLL	TREANDA.xml:S1:752:3	O
(	TREANDA.xml:S1:756:1	O
frequency	TREANDA.xml:S1:757:9	O
15%	TREANDA.xml:S1:770:3	O
)	TREANDA.xml:S1:773:1	O
are	TREANDA.xml:S1:775:3	O
pyrexia	TREANDA.xml:S1:779:7	B-AdverseReaction
,	TREANDA.xml:S1:786:1	O
nausea	TREANDA.xml:S1:788:6	B-AdverseReaction
,	TREANDA.xml:S1:794:1	O
and	TREANDA.xml:S1:796:3	O
vomiting	TREANDA.xml:S1:800:8	B-AdverseReaction
.	TREANDA.xml:S1:808:1	O

(	TREANDA.xml:S1:810:1	O
6.1	TREANDA.xml:S1:813:3	O
)	TREANDA.xml:S1:818:1	O

Most	TREANDA.xml:S1:829:4	O
common	TREANDA.xml:S1:834:6	O
non	TREANDA.xml:S1:841:3	O
-	TREANDA.xml:S1:844:1	O
hematologic	TREANDA.xml:S1:845:11	O
adverse	TREANDA.xml:S1:857:7	O
reactions	TREANDA.xml:S1:865:9	O
for	TREANDA.xml:S1:875:3	O
NHL	TREANDA.xml:S1:879:3	O
(	TREANDA.xml:S1:883:1	O
frequency	TREANDA.xml:S1:884:9	O
15%	TREANDA.xml:S1:897:3	O
)	TREANDA.xml:S1:900:1	O
are	TREANDA.xml:S1:902:3	O
nausea	TREANDA.xml:S1:906:6	B-AdverseReaction
,	TREANDA.xml:S1:912:1	O
fatigue	TREANDA.xml:S1:914:7	B-AdverseReaction
,	TREANDA.xml:S1:921:1	O
vomiting	TREANDA.xml:S1:923:8	B-AdverseReaction
,	TREANDA.xml:S1:931:1	O
diarrhea	TREANDA.xml:S1:933:8	B-AdverseReaction
,	TREANDA.xml:S1:941:1	O
pyrexia	TREANDA.xml:S1:943:7	B-AdverseReaction
,	TREANDA.xml:S1:950:1	O
constipation	TREANDA.xml:S1:952:12	B-AdverseReaction
,	TREANDA.xml:S1:964:1	O
anorexia	TREANDA.xml:S1:966:8	B-AdverseReaction
,	TREANDA.xml:S1:974:1	O
cough	TREANDA.xml:S1:976:5	B-AdverseReaction
,	TREANDA.xml:S1:981:1	O
headache	TREANDA.xml:S1:983:8	B-AdverseReaction
,	TREANDA.xml:S1:991:1	O
weight	TREANDA.xml:S1:993:6	B-AdverseReaction
decreased	TREANDA.xml:S1:1000:9	I-AdverseReaction
,	TREANDA.xml:S1:1009:1	O
dyspnea	TREANDA.xml:S1:1011:7	B-AdverseReaction
,	TREANDA.xml:S1:1018:1	O
rash	TREANDA.xml:S1:1020:4	B-AdverseReaction
,	TREANDA.xml:S1:1024:1	O
and	TREANDA.xml:S1:1026:3	O
stomatitis	TREANDA.xml:S1:1030:10	B-AdverseReaction
.	TREANDA.xml:S1:1040:1	O

(	TREANDA.xml:S1:1042:1	O
6.1	TREANDA.xml:S1:1045:3	O
)	TREANDA.xml:S1:1050:1	O

Most	TREANDA.xml:S1:1062:4	O
common	TREANDA.xml:S1:1067:6	O
hematologic	TREANDA.xml:S1:1074:11	B-AdverseReaction
abnormalities	TREANDA.xml:S1:1086:13	I-AdverseReaction
for	TREANDA.xml:S1:1100:3	O
both	TREANDA.xml:S1:1104:4	O
indications	TREANDA.xml:S1:1109:11	O
(	TREANDA.xml:S1:1121:1	O
frequency	TREANDA.xml:S1:1122:9	O
15%	TREANDA.xml:S1:1135:3	O
)	TREANDA.xml:S1:1138:1	O
are	TREANDA.xml:S1:1140:3	O
lymphopenia	TREANDA.xml:S1:1144:11	B-AdverseReaction
,	TREANDA.xml:S1:1155:1	O
anemia	TREANDA.xml:S1:1157:6	B-AdverseReaction
,	TREANDA.xml:S1:1163:1	O
leukopenia	TREANDA.xml:S1:1165:10	B-AdverseReaction
,	TREANDA.xml:S1:1175:1	O
thrombocytopenia	TREANDA.xml:S1:1177:16	B-AdverseReaction
,	TREANDA.xml:S1:1193:1	O
and	TREANDA.xml:S1:1195:3	O
neutropenia	TREANDA.xml:S1:1199:11	B-AdverseReaction
.	TREANDA.xml:S1:1210:1	O

(	TREANDA.xml:S1:1212:1	O
6.1	TREANDA.xml:S1:1215:3	O
)	TREANDA.xml:S1:1220:1	O

EXCERPT	TREANDA.xml:S1:1229:7	O
:	TREANDA.xml:S1:1236:1	O
To	TREANDA.xml:S1:1242:2	O
report	TREANDA.xml:S1:1245:6	O
SUSPECTED	TREANDA.xml:S1:1252:9	O
ADVERSE	TREANDA.xml:S1:1262:7	O
REACTIONS	TREANDA.xml:S1:1270:9	O
,	TREANDA.xml:S1:1279:1	O
contact	TREANDA.xml:S1:1281:7	O
Teva	TREANDA.xml:S1:1289:4	O
Pharmaceuticals	TREANDA.xml:S1:1294:15	O
at	TREANDA.xml:S1:1310:2	O
1	TREANDA.xml:S1:1313:1	O
-	TREANDA.xml:S1:1314:1	O
800	TREANDA.xml:S1:1315:3	O
-	TREANDA.xml:S1:1318:1	O
896	TREANDA.xml:S1:1319:3	O
-	TREANDA.xml:S1:1322:1	O
5855	TREANDA.xml:S1:1323:4	O
or	TREANDA.xml:S1:1328:2	O
FDA	TREANDA.xml:S1:1331:3	O
at	TREANDA.xml:S1:1335:2	O
1	TREANDA.xml:S1:1338:1	O
-	TREANDA.xml:S1:1339:1	O
800	TREANDA.xml:S1:1340:3	O
-	TREANDA.xml:S1:1343:1	O
FDA	TREANDA.xml:S1:1344:3	O
-	TREANDA.xml:S1:1347:1	O
1088	TREANDA.xml:S1:1348:4	O
or	TREANDA.xml:S1:1353:2	O
www	TREANDA.xml:S1:1359:3	O
.	TREANDA.xml:S1:1362:1	O
fda	TREANDA.xml:S1:1363:3	O
.	TREANDA.xml:S1:1366:1	O
gov	TREANDA.xml:S1:1367:3	O
medwatch	TREANDA.xml:S1:1371:8	O
.	TREANDA.xml:S1:1383:1	O

6.1	TREANDA.xml:S1:1395:3	O

Clinical	TREANDA.xml:S1:1399:8	O

Trials	TREANDA.xml:S1:1408:6	O
Experience	TREANDA.xml:S1:1415:10	O

Because	TREANDA.xml:S1:1429:7	O
clinical	TREANDA.xml:S1:1437:8	O
trials	TREANDA.xml:S1:1446:6	O
are	TREANDA.xml:S1:1453:3	O
conducted	TREANDA.xml:S1:1457:9	O
under	TREANDA.xml:S1:1467:5	O
widely	TREANDA.xml:S1:1473:6	O
varying	TREANDA.xml:S1:1480:7	O
conditions	TREANDA.xml:S1:1488:10	O
,	TREANDA.xml:S1:1498:1	O
adverse	TREANDA.xml:S1:1500:7	O
reaction	TREANDA.xml:S1:1508:8	O
rates	TREANDA.xml:S1:1517:5	O
observed	TREANDA.xml:S1:1523:8	O
in	TREANDA.xml:S1:1532:2	O
the	TREANDA.xml:S1:1535:3	O
clinical	TREANDA.xml:S1:1539:8	O
trials	TREANDA.xml:S1:1548:6	O
of	TREANDA.xml:S1:1555:2	O
a	TREANDA.xml:S1:1558:1	O
drug	TREANDA.xml:S1:1560:4	O
cannot	TREANDA.xml:S1:1565:6	O
be	TREANDA.xml:S1:1572:2	O
directly	TREANDA.xml:S1:1575:8	O
compared	TREANDA.xml:S1:1584:8	O
to	TREANDA.xml:S1:1593:2	O
rates	TREANDA.xml:S1:1596:5	O
in	TREANDA.xml:S1:1602:2	O
the	TREANDA.xml:S1:1605:3	O
clinical	TREANDA.xml:S1:1609:8	O
trials	TREANDA.xml:S1:1618:6	O
of	TREANDA.xml:S1:1625:2	O
another	TREANDA.xml:S1:1628:7	O
drug	TREANDA.xml:S1:1636:4	O
and	TREANDA.xml:S1:1641:3	O
may	TREANDA.xml:S1:1645:3	O
not	TREANDA.xml:S1:1649:3	O
reflect	TREANDA.xml:S1:1653:7	O
the	TREANDA.xml:S1:1661:3	O
rates	TREANDA.xml:S1:1665:5	O
observed	TREANDA.xml:S1:1671:8	O
in	TREANDA.xml:S1:1680:2	O
practice	TREANDA.xml:S1:1683:8	O
.	TREANDA.xml:S1:1691:1	O

Chronic	TREANDA.xml:S1:1699:7	O
Lymphocytic	TREANDA.xml:S1:1707:11	O
Leukemia	TREANDA.xml:S1:1719:8	O

The	TREANDA.xml:S1:1734:3	O
data	TREANDA.xml:S1:1738:4	O
described	TREANDA.xml:S1:1743:9	O
below	TREANDA.xml:S1:1753:5	O
reflect	TREANDA.xml:S1:1759:7	O
exposure	TREANDA.xml:S1:1767:8	O
to	TREANDA.xml:S1:1776:2	O
TREANDA	TREANDA.xml:S1:1779:7	O
in	TREANDA.xml:S1:1787:2	O
153	TREANDA.xml:S1:1790:3	O
patients	TREANDA.xml:S1:1794:8	O
with	TREANDA.xml:S1:1803:4	O
CLL	TREANDA.xml:S1:1808:3	O
studied	TREANDA.xml:S1:1812:7	O
in	TREANDA.xml:S1:1820:2	O
an	TREANDA.xml:S1:1823:2	O
active	TREANDA.xml:S1:1826:6	O
-	TREANDA.xml:S1:1832:1	O
controlled	TREANDA.xml:S1:1833:10	O
,	TREANDA.xml:S1:1843:1	O
randomized	TREANDA.xml:S1:1845:10	O
trial	TREANDA.xml:S1:1856:5	O
.	TREANDA.xml:S1:1861:1	O

The	TREANDA.xml:S1:1864:3	O
population	TREANDA.xml:S1:1868:10	O
was	TREANDA.xml:S1:1879:3	O
45	TREANDA.xml:S1:1883:2	O
-	TREANDA.xml:S1:1885:1	O
77	TREANDA.xml:S1:1886:2	O
years	TREANDA.xml:S1:1889:5	O
of	TREANDA.xml:S1:1895:2	O
age	TREANDA.xml:S1:1898:3	O
,	TREANDA.xml:S1:1901:1	O
63%	TREANDA.xml:S1:1903:3	O
male	TREANDA.xml:S1:1907:4	O
,	TREANDA.xml:S1:1911:1	O
100%	TREANDA.xml:S1:1913:4	O
white	TREANDA.xml:S1:1918:5	O
,	TREANDA.xml:S1:1923:1	O
and	TREANDA.xml:S1:1925:3	O
were	TREANDA.xml:S1:1929:4	O
treatment	TREANDA.xml:S1:1934:9	O
naive	TREANDA.xml:S1:1944:5	O
.	TREANDA.xml:S1:1949:1	O

All	TREANDA.xml:S1:1951:3	O
patients	TREANDA.xml:S1:1955:8	O
started	TREANDA.xml:S1:1964:7	O
the	TREANDA.xml:S1:1972:3	O
study	TREANDA.xml:S1:1976:5	O
at	TREANDA.xml:S1:1982:2	O
a	TREANDA.xml:S1:1985:1	O
dose	TREANDA.xml:S1:1987:4	O
of	TREANDA.xml:S1:1992:2	O
100	TREANDA.xml:S1:1995:3	O
mg	TREANDA.xml:S1:1999:2	O
m	TREANDA.xml:S1:2002:1	O
2	TREANDA.xml:S1:2005:1	O
intravenously	TREANDA.xml:S1:2008:13	O
over	TREANDA.xml:S1:2022:4	O
30	TREANDA.xml:S1:2027:2	O
minutes	TREANDA.xml:S1:2030:7	O
on	TREANDA.xml:S1:2038:2	O
Days	TREANDA.xml:S1:2041:4	O
1	TREANDA.xml:S1:2046:1	O
and	TREANDA.xml:S1:2048:3	O
2	TREANDA.xml:S1:2052:1	O
every	TREANDA.xml:S1:2054:5	O
28	TREANDA.xml:S1:2060:2	O
days	TREANDA.xml:S1:2063:4	O
.	TREANDA.xml:S1:2067:1	O

Adverse	TREANDA.xml:S1:2074:7	O
reactions	TREANDA.xml:S1:2082:9	O
were	TREANDA.xml:S1:2092:4	O
reported	TREANDA.xml:S1:2097:8	O
according	TREANDA.xml:S1:2106:9	O
to	TREANDA.xml:S1:2116:2	O
NCI	TREANDA.xml:S1:2119:3	O
CTC	TREANDA.xml:S1:2123:3	O
v	TREANDA.xml:S1:2127:1	O
.	TREANDA.xml:S1:2128:1	O
2.0	TREANDA.xml:S1:2129:3	O
.	TREANDA.xml:S1:2132:1	O

Non	TREANDA.xml:S1:2135:3	O
-	TREANDA.xml:S1:2138:1	O
hematologic	TREANDA.xml:S1:2139:11	O
adverse	TREANDA.xml:S1:2151:7	O
reactions	TREANDA.xml:S1:2159:9	O
(	TREANDA.xml:S1:2169:1	O
any	TREANDA.xml:S1:2170:3	O
grade	TREANDA.xml:S1:2174:5	O
)	TREANDA.xml:S1:2179:1	O
in	TREANDA.xml:S1:2181:2	O
the	TREANDA.xml:S1:2184:3	O
TREANDA	TREANDA.xml:S1:2188:7	O
group	TREANDA.xml:S1:2196:5	O
that	TREANDA.xml:S1:2202:4	O
occurred	TREANDA.xml:S1:2207:8	O
with	TREANDA.xml:S1:2216:4	O
a	TREANDA.xml:S1:2221:1	O
frequency	TREANDA.xml:S1:2223:9	O
greater	TREANDA.xml:S1:2233:7	O
than	TREANDA.xml:S1:2241:4	O
15%	TREANDA.xml:S1:2246:3	O
were	TREANDA.xml:S1:2250:4	O
pyrexia	TREANDA.xml:S1:2255:7	B-AdverseReaction
(	TREANDA.xml:S1:2263:1	O
24%	TREANDA.xml:S1:2264:3	O
)	TREANDA.xml:S1:2267:1	O
,	TREANDA.xml:S1:2268:1	O
nausea	TREANDA.xml:S1:2270:6	B-AdverseReaction
(	TREANDA.xml:S1:2277:1	O
20%	TREANDA.xml:S1:2278:3	O
)	TREANDA.xml:S1:2281:1	O
,	TREANDA.xml:S1:2282:1	O
and	TREANDA.xml:S1:2284:3	O
vomiting	TREANDA.xml:S1:2288:8	B-AdverseReaction
(	TREANDA.xml:S1:2297:1	O
16%	TREANDA.xml:S1:2298:3	O
)	TREANDA.xml:S1:2301:1	O
.	TREANDA.xml:S1:2302:1	O

Other	TREANDA.xml:S1:2310:5	O
adverse	TREANDA.xml:S1:2316:7	O
reactions	TREANDA.xml:S1:2324:9	O
seen	TREANDA.xml:S1:2334:4	O
frequently	TREANDA.xml:S1:2339:10	O
in	TREANDA.xml:S1:2350:2	O
one	TREANDA.xml:S1:2353:3	O
or	TREANDA.xml:S1:2357:2	O
more	TREANDA.xml:S1:2360:4	O
studies	TREANDA.xml:S1:2365:7	O
included	TREANDA.xml:S1:2373:8	O
asthenia	TREANDA.xml:S1:2382:8	B-AdverseReaction
,	TREANDA.xml:S1:2390:1	O
fatigue	TREANDA.xml:S1:2392:7	B-AdverseReaction
,	TREANDA.xml:S1:2399:1	O
malaise	TREANDA.xml:S1:2401:7	B-AdverseReaction
,	TREANDA.xml:S1:2408:1	O
and	TREANDA.xml:S1:2410:3	O
weakness	TREANDA.xml:S1:2414:8	B-AdverseReaction
;	TREANDA.xml:S1:2422:1	O
dry	TREANDA.xml:S1:2424:3	B-AdverseReaction
mouth	TREANDA.xml:S1:2428:5	I-AdverseReaction
;	TREANDA.xml:S1:2433:1	O
somnolence	TREANDA.xml:S1:2435:10	B-AdverseReaction
;	TREANDA.xml:S1:2445:1	O
cough	TREANDA.xml:S1:2447:5	B-AdverseReaction
;	TREANDA.xml:S1:2452:1	O
constipation	TREANDA.xml:S1:2454:12	B-AdverseReaction
;	TREANDA.xml:S1:2466:1	O
headache	TREANDA.xml:S1:2468:8	B-AdverseReaction
;	TREANDA.xml:S1:2476:1	O
mucosal	TREANDA.xml:S1:2478:7	B-AdverseReaction
inflammation	TREANDA.xml:S1:2486:12	I-AdverseReaction
and	TREANDA.xml:S1:2499:3	O
stomatitis	TREANDA.xml:S1:2503:10	B-AdverseReaction
.	TREANDA.xml:S1:2513:1	O

Worsening	TREANDA.xml:S1:2520:9	B-AdverseReaction
hypertension	TREANDA.xml:S1:2530:12	I-AdverseReaction
was	TREANDA.xml:S1:2543:3	O
reported	TREANDA.xml:S1:2547:8	O
in	TREANDA.xml:S1:2556:2	O
4	TREANDA.xml:S1:2559:1	O
patients	TREANDA.xml:S1:2561:8	O
treated	TREANDA.xml:S1:2570:7	O
with	TREANDA.xml:S1:2578:4	O
TREANDA	TREANDA.xml:S1:2583:7	O
in	TREANDA.xml:S1:2591:2	O
the	TREANDA.xml:S1:2594:3	O
CLL	TREANDA.xml:S1:2598:3	O
trial	TREANDA.xml:S1:2602:5	O
and	TREANDA.xml:S1:2608:3	O
in	TREANDA.xml:S1:2612:2	O
none	TREANDA.xml:S1:2615:4	O
treated	TREANDA.xml:S1:2620:7	O
with	TREANDA.xml:S1:2628:4	O
chlorambucil	TREANDA.xml:S1:2633:12	O
.	TREANDA.xml:S1:2645:1	O

Three	TREANDA.xml:S1:2648:5	O
of	TREANDA.xml:S1:2654:2	O
these	TREANDA.xml:S1:2657:5	O
4	TREANDA.xml:S1:2663:1	O
adverse	TREANDA.xml:S1:2665:7	O
reactions	TREANDA.xml:S1:2673:9	O
were	TREANDA.xml:S1:2683:4	O
described	TREANDA.xml:S1:2688:9	O
as	TREANDA.xml:S1:2698:2	O
a	TREANDA.xml:S1:2701:1	O
hypertensive	TREANDA.xml:S1:2703:12	B-AdverseReaction
crisis	TREANDA.xml:S1:2716:6	I-AdverseReaction
and	TREANDA.xml:S1:2723:3	O
were	TREANDA.xml:S1:2727:4	O
managed	TREANDA.xml:S1:2732:7	O
with	TREANDA.xml:S1:2740:4	O
oral	TREANDA.xml:S1:2745:4	O
medications	TREANDA.xml:S1:2750:11	O
and	TREANDA.xml:S1:2762:3	O
resolved	TREANDA.xml:S1:2766:8	O
.	TREANDA.xml:S1:2774:1	O

The	TREANDA.xml:S1:2780:3	O
most	TREANDA.xml:S1:2784:4	O
frequent	TREANDA.xml:S1:2789:8	O
adverse	TREANDA.xml:S1:2798:7	O
reactions	TREANDA.xml:S1:2806:9	O
leading	TREANDA.xml:S1:2816:7	O
to	TREANDA.xml:S1:2824:2	O
study	TREANDA.xml:S1:2827:5	O
withdrawal	TREANDA.xml:S1:2833:10	O
for	TREANDA.xml:S1:2844:3	O
patients	TREANDA.xml:S1:2848:8	O
receiving	TREANDA.xml:S1:2857:9	O
TREANDA	TREANDA.xml:S1:2867:7	O
were	TREANDA.xml:S1:2875:4	O
hypersensitivity	TREANDA.xml:S1:2880:16	B-AdverseReaction
(	TREANDA.xml:S1:2897:1	O
2%	TREANDA.xml:S1:2898:2	O
)	TREANDA.xml:S1:2900:1	O
and	TREANDA.xml:S1:2902:3	O
pyrexia	TREANDA.xml:S1:2906:7	B-AdverseReaction
(	TREANDA.xml:S1:2914:1	O
1%	TREANDA.xml:S1:2915:2	O
)	TREANDA.xml:S1:2917:1	O
.	TREANDA.xml:S1:2918:1	O

Table	TREANDA.xml:S1:2924:5	O
1	TREANDA.xml:S1:2930:1	O
contains	TREANDA.xml:S1:2932:8	O
the	TREANDA.xml:S1:2941:3	O
treatment	TREANDA.xml:S1:2945:9	O
emergent	TREANDA.xml:S1:2955:8	O
adverse	TREANDA.xml:S1:2964:7	O
reactions	TREANDA.xml:S1:2972:9	O
,	TREANDA.xml:S1:2981:1	O
regardless	TREANDA.xml:S1:2983:10	O
of	TREANDA.xml:S1:2994:2	O
attribution	TREANDA.xml:S1:2997:11	O
,	TREANDA.xml:S1:3008:1	O
that	TREANDA.xml:S1:3010:4	O
were	TREANDA.xml:S1:3015:4	O
reported	TREANDA.xml:S1:3020:8	O
in	TREANDA.xml:S1:3029:2	O
5%	TREANDA.xml:S1:3035:2	O
of	TREANDA.xml:S1:3038:2	O
patients	TREANDA.xml:S1:3041:8	O
in	TREANDA.xml:S1:3050:2	O
either	TREANDA.xml:S1:3053:6	O
treatment	TREANDA.xml:S1:3060:9	O
group	TREANDA.xml:S1:3070:5	O
in	TREANDA.xml:S1:3076:2	O
the	TREANDA.xml:S1:3079:3	O
randomized	TREANDA.xml:S1:3083:10	O
CLL	TREANDA.xml:S1:3094:3	O
clinical	TREANDA.xml:S1:3098:8	O
study	TREANDA.xml:S1:3107:5	O
.	TREANDA.xml:S1:3112:1	O

Table	TREANDA.xml:S1:3118:5	O
1	TREANDA.xml:S1:3124:1	O
:	TREANDA.xml:S1:3125:1	O
Non	TREANDA.xml:S1:3127:3	O
-	TREANDA.xml:S1:3130:1	O
Hematologic	TREANDA.xml:S1:3131:11	O
Adverse	TREANDA.xml:S1:3143:7	O
Reactions	TREANDA.xml:S1:3151:9	O
Occurring	TREANDA.xml:S1:3161:9	O
in	TREANDA.xml:S1:3171:2	O
Randomized	TREANDA.xml:S1:3174:10	O
CLL	TREANDA.xml:S1:3185:3	O
Clinical	TREANDA.xml:S1:3189:8	O
Study	TREANDA.xml:S1:3198:5	O
in	TREANDA.xml:S1:3204:2	O
at	TREANDA.xml:S1:3207:2	O
Least	TREANDA.xml:S1:3210:5	O
5%	TREANDA.xml:S1:3216:2	O
of	TREANDA.xml:S1:3219:2	O
Patients	TREANDA.xml:S1:3222:8	O

Number	TREANDA.xml:S1:3289:6	O
(	TREANDA.xml:S1:3296:1	O
)	TREANDA.xml:S1:3298:1	O
of	TREANDA.xml:S1:3300:2	O
patients	TREANDA.xml:S1:3303:8	O

TREANDA	TREANDA.xml:S1:3372:7	O
(	TREANDA.xml:S1:3379:1	O
N	TREANDA.xml:S1:3380:1	O
153	TREANDA.xml:S1:3382:3	O
)	TREANDA.xml:S1:3385:1	O
Chlorambucil	TREANDA.xml:S1:3390:12	O
(	TREANDA.xml:S1:3402:1	O
N	TREANDA.xml:S1:3403:1	O
143	TREANDA.xml:S1:3405:3	O
)	TREANDA.xml:S1:3408:1	O

System	TREANDA.xml:S1:3416:6	O
organ	TREANDA.xml:S1:3423:5	O
class	TREANDA.xml:S1:3429:5	O
Preferred	TREANDA.xml:S1:3439:9	O
term	TREANDA.xml:S1:3449:4	O
All	TREANDA.xml:S1:3470:3	O
Grades	TREANDA.xml:S1:3474:6	O
Grade	TREANDA.xml:S1:3485:5	O
3	TREANDA.xml:S1:3491:1	O
4	TREANDA.xml:S1:3493:1	O
All	TREANDA.xml:S1:3499:3	O
Grades	TREANDA.xml:S1:3503:6	O
Grade	TREANDA.xml:S1:3514:5	O
3	TREANDA.xml:S1:3520:1	O
4	TREANDA.xml:S1:3522:1	O

Total	TREANDA.xml:S1:3531:5	O
number	TREANDA.xml:S1:3537:6	O
of	TREANDA.xml:S1:3544:2	O
patients	TREANDA.xml:S1:3547:8	O
with	TREANDA.xml:S1:3556:4	O
at	TREANDA.xml:S1:3561:2	O
least	TREANDA.xml:S1:3564:5	O
1	TREANDA.xml:S1:3570:1	O
adverse	TREANDA.xml:S1:3572:7	O
reaction	TREANDA.xml:S1:3580:8	O
121	TREANDA.xml:S1:3592:3	O
(	TREANDA.xml:S1:3596:1	O
79	TREANDA.xml:S1:3597:2	O
)	TREANDA.xml:S1:3599:1	O
52	TREANDA.xml:S1:3606:2	O
(	TREANDA.xml:S1:3609:1	O
34	TREANDA.xml:S1:3610:2	O
)	TREANDA.xml:S1:3612:1	O
96	TREANDA.xml:S1:3619:2	O
(	TREANDA.xml:S1:3622:1	O
67	TREANDA.xml:S1:3623:2	O
)	TREANDA.xml:S1:3625:1	O
25	TREANDA.xml:S1:3633:2	O
(	TREANDA.xml:S1:3636:1	O
17	TREANDA.xml:S1:3637:2	O
)	TREANDA.xml:S1:3639:1	O

Gastrointestinal	TREANDA.xml:S1:3649:16	O
disorders	TREANDA.xml:S1:3666:9	O

Nausea	TREANDA.xml:S1:3762:6	B-AdverseReaction
31	TREANDA.xml:S1:3814:2	O
(	TREANDA.xml:S1:3817:1	O
20	TREANDA.xml:S1:3818:2	O
)	TREANDA.xml:S1:3820:1	O
1	TREANDA.xml:S1:3828:1	O
(	TREANDA.xml:S1:3830:1	O
1	TREANDA.xml:S1:3832:1	O
)	TREANDA.xml:S1:3833:1	O
21	TREANDA.xml:S1:3841:2	O
(	TREANDA.xml:S1:3844:1	O
15	TREANDA.xml:S1:3845:2	O
)	TREANDA.xml:S1:3847:1	O
1	TREANDA.xml:S1:3855:1	O
(	TREANDA.xml:S1:3857:1	O
1	TREANDA.xml:S1:3859:1	O
)	TREANDA.xml:S1:3860:1	O

Vomiting	TREANDA.xml:S1:3873:8	B-AdverseReaction
24	TREANDA.xml:S1:3925:2	O
(	TREANDA.xml:S1:3928:1	O
16	TREANDA.xml:S1:3929:2	O
)	TREANDA.xml:S1:3931:1	O
1	TREANDA.xml:S1:3939:1	O
(	TREANDA.xml:S1:3941:1	O
1	TREANDA.xml:S1:3943:1	O
)	TREANDA.xml:S1:3944:1	O
9	TREANDA.xml:S1:3952:1	O
(	TREANDA.xml:S1:3954:1	O
6	TREANDA.xml:S1:3955:1	O
)	TREANDA.xml:S1:3956:1	O
0	TREANDA.xml:S1:3966:1	O

Diarrhea	TREANDA.xml:S1:3984:8	B-AdverseReaction
14	TREANDA.xml:S1:4036:2	O
(	TREANDA.xml:S1:4039:1	O
9	TREANDA.xml:S1:4040:1	O
)	TREANDA.xml:S1:4041:1	O
2	TREANDA.xml:S1:4050:1	O
(	TREANDA.xml:S1:4052:1	O
1	TREANDA.xml:S1:4053:1	O
)	TREANDA.xml:S1:4054:1	O
5	TREANDA.xml:S1:4063:1	O
(	TREANDA.xml:S1:4065:1	O
3	TREANDA.xml:S1:4066:1	O
)	TREANDA.xml:S1:4067:1	O
0	TREANDA.xml:S1:4077:1	O

General	TREANDA.xml:S1:4093:7	O
disorders	TREANDA.xml:S1:4101:9	O
and	TREANDA.xml:S1:4111:3	O
administration	TREANDA.xml:S1:4115:14	O
site	TREANDA.xml:S1:4130:4	O
conditions	TREANDA.xml:S1:4135:10	O

Pyrexia	TREANDA.xml:S1:4208:7	B-AdverseReaction
36	TREANDA.xml:S1:4260:2	O
(	TREANDA.xml:S1:4263:1	O
24	TREANDA.xml:S1:4264:2	O
)	TREANDA.xml:S1:4266:1	O
6	TREANDA.xml:S1:4274:1	O
(	TREANDA.xml:S1:4276:1	O
4	TREANDA.xml:S1:4277:1	O
)	TREANDA.xml:S1:4278:1	O
8	TREANDA.xml:S1:4287:1	O
(	TREANDA.xml:S1:4289:1	O
6	TREANDA.xml:S1:4290:1	O
)	TREANDA.xml:S1:4291:1	O
2	TREANDA.xml:S1:4301:1	O
(	TREANDA.xml:S1:4303:1	O
1	TREANDA.xml:S1:4304:1	O
)	TREANDA.xml:S1:4305:1	O

Fatigue	TREANDA.xml:S1:4319:7	B-AdverseReaction
14	TREANDA.xml:S1:4371:2	O
(	TREANDA.xml:S1:4374:1	O
9	TREANDA.xml:S1:4375:1	O
)	TREANDA.xml:S1:4376:1	O
2	TREANDA.xml:S1:4385:1	O
(	TREANDA.xml:S1:4387:1	O
1	TREANDA.xml:S1:4388:1	O
)	TREANDA.xml:S1:4389:1	O
8	TREANDA.xml:S1:4398:1	O
(	TREANDA.xml:S1:4400:1	O
6	TREANDA.xml:S1:4401:1	O
)	TREANDA.xml:S1:4402:1	O
0	TREANDA.xml:S1:4412:1	O

Asthenia	TREANDA.xml:S1:4430:8	B-AdverseReaction
13	TREANDA.xml:S1:4482:2	O
(	TREANDA.xml:S1:4485:1	O
8	TREANDA.xml:S1:4486:1	O
)	TREANDA.xml:S1:4487:1	O
0	TREANDA.xml:S1:4496:1	O
6	TREANDA.xml:S1:4509:1	O
(	TREANDA.xml:S1:4511:1	O
4	TREANDA.xml:S1:4512:1	O
)	TREANDA.xml:S1:4513:1	O
0	TREANDA.xml:S1:4523:1	O

Chills	TREANDA.xml:S1:4541:6	B-AdverseReaction
9	TREANDA.xml:S1:4593:1	O
(	TREANDA.xml:S1:4595:1	O
6	TREANDA.xml:S1:4596:1	O
)	TREANDA.xml:S1:4597:1	O
0	TREANDA.xml:S1:4607:1	O
1	TREANDA.xml:S1:4620:1	O
(	TREANDA.xml:S1:4622:1	O
1	TREANDA.xml:S1:4624:1	O
)	TREANDA.xml:S1:4625:1	O
0	TREANDA.xml:S1:4634:1	O

Immune	TREANDA.xml:S1:4650:6	O
system	TREANDA.xml:S1:4657:6	O
disorders	TREANDA.xml:S1:4664:9	O

Hypersensitivity	TREANDA.xml:S1:4763:16	B-AdverseReaction
7	TREANDA.xml:S1:4815:1	O
(	TREANDA.xml:S1:4817:1	O
5	TREANDA.xml:S1:4818:1	O
)	TREANDA.xml:S1:4819:1	O
2	TREANDA.xml:S1:4829:1	O
(	TREANDA.xml:S1:4831:1	O
1	TREANDA.xml:S1:4832:1	O
)	TREANDA.xml:S1:4833:1	O
3	TREANDA.xml:S1:4842:1	O
(	TREANDA.xml:S1:4844:1	O
2	TREANDA.xml:S1:4845:1	O
)	TREANDA.xml:S1:4846:1	O
0	TREANDA.xml:S1:4856:1	O

Infections	TREANDA.xml:S1:4872:10	O
and	TREANDA.xml:S1:4883:3	O
infestations	TREANDA.xml:S1:4887:12	O

Nasopharyngitis	TREANDA.xml:S1:4985:15	B-AdverseReaction
10	TREANDA.xml:S1:5037:2	O
(	TREANDA.xml:S1:5040:1	O
7	TREANDA.xml:S1:5041:1	O
)	TREANDA.xml:S1:5042:1	O
0	TREANDA.xml:S1:5051:1	O
12	TREANDA.xml:S1:5064:2	O
(	TREANDA.xml:S1:5067:1	O
8	TREANDA.xml:S1:5068:1	O
)	TREANDA.xml:S1:5069:1	O
0	TREANDA.xml:S1:5078:1	O

Infection	TREANDA.xml:S1:5096:9	B-AdverseReaction
9	TREANDA.xml:S1:5148:1	O
(	TREANDA.xml:S1:5150:1	O
6	TREANDA.xml:S1:5151:1	O
)	TREANDA.xml:S1:5152:1	O
3	TREANDA.xml:S1:5162:1	O
(	TREANDA.xml:S1:5164:1	O
2	TREANDA.xml:S1:5165:1	O
)	TREANDA.xml:S1:5166:1	O
1	TREANDA.xml:S1:5175:1	O
(	TREANDA.xml:S1:5177:1	O
1	TREANDA.xml:S1:5179:1	O
)	TREANDA.xml:S1:5180:1	O
1	TREANDA.xml:S1:5189:1	O
(	TREANDA.xml:S1:5191:1	O
1	TREANDA.xml:S1:5193:1	O
)	TREANDA.xml:S1:5194:1	O

Herpes	TREANDA.xml:S1:5207:6	B-AdverseReaction
simplex	TREANDA.xml:S1:5214:7	I-AdverseReaction
5	TREANDA.xml:S1:5259:1	O
(	TREANDA.xml:S1:5261:1	O
3	TREANDA.xml:S1:5262:1	O
)	TREANDA.xml:S1:5263:1	O
0	TREANDA.xml:S1:5273:1	O
7	TREANDA.xml:S1:5286:1	O
(	TREANDA.xml:S1:5288:1	O
5	TREANDA.xml:S1:5289:1	O
)	TREANDA.xml:S1:5290:1	O
0	TREANDA.xml:S1:5300:1	O

Investigations	TREANDA.xml:S1:5316:14	O

Weight	TREANDA.xml:S1:5429:6	B-AdverseReaction
decreased	TREANDA.xml:S1:5436:9	I-AdverseReaction
11	TREANDA.xml:S1:5481:2	O
(	TREANDA.xml:S1:5484:1	O
7	TREANDA.xml:S1:5485:1	O
)	TREANDA.xml:S1:5486:1	O
0	TREANDA.xml:S1:5495:1	O
5	TREANDA.xml:S1:5508:1	O
(	TREANDA.xml:S1:5510:1	O
3	TREANDA.xml:S1:5511:1	O
)	TREANDA.xml:S1:5512:1	O
0	TREANDA.xml:S1:5522:1	O

Metabolism	TREANDA.xml:S1:5538:10	O
and	TREANDA.xml:S1:5549:3	O
nutrition	TREANDA.xml:S1:5553:9	O
disorders	TREANDA.xml:S1:5563:9	O

Hyperuricemia	TREANDA.xml:S1:5651:13	B-AdverseReaction
11	TREANDA.xml:S1:5703:2	O
(	TREANDA.xml:S1:5706:1	O
7	TREANDA.xml:S1:5707:1	O
)	TREANDA.xml:S1:5708:1	O
3	TREANDA.xml:S1:5717:1	O
(	TREANDA.xml:S1:5719:1	O
2	TREANDA.xml:S1:5720:1	O
)	TREANDA.xml:S1:5721:1	O
2	TREANDA.xml:S1:5730:1	O
(	TREANDA.xml:S1:5732:1	O
1	TREANDA.xml:S1:5733:1	O
)	TREANDA.xml:S1:5734:1	O
0	TREANDA.xml:S1:5744:1	O

Respiratory	TREANDA.xml:S1:5760:11	O
,	TREANDA.xml:S1:5771:1	O
thoracic	TREANDA.xml:S1:5773:8	O
and	TREANDA.xml:S1:5782:3	O
mediastinal	TREANDA.xml:S1:5786:11	O
disorders	TREANDA.xml:S1:5798:9	O

Cough	TREANDA.xml:S1:5873:5	B-AdverseReaction
6	TREANDA.xml:S1:5925:1	O
(	TREANDA.xml:S1:5927:1	O
4	TREANDA.xml:S1:5928:1	O
)	TREANDA.xml:S1:5929:1	O
1	TREANDA.xml:S1:5939:1	O
(	TREANDA.xml:S1:5941:1	O
1	TREANDA.xml:S1:5943:1	O
)	TREANDA.xml:S1:5944:1	O
7	TREANDA.xml:S1:5952:1	O
(	TREANDA.xml:S1:5954:1	O
5	TREANDA.xml:S1:5955:1	O
)	TREANDA.xml:S1:5956:1	O
1	TREANDA.xml:S1:5966:1	O
(	TREANDA.xml:S1:5968:1	O
1	TREANDA.xml:S1:5970:1	O
)	TREANDA.xml:S1:5971:1	O

Skin	TREANDA.xml:S1:5982:4	O
and	TREANDA.xml:S1:5987:3	O
subcutaneous	TREANDA.xml:S1:5991:12	O
tissue	TREANDA.xml:S1:6004:6	O
disorders	TREANDA.xml:S1:6011:9	O

Rash	TREANDA.xml:S1:6095:4	B-AdverseReaction
12	TREANDA.xml:S1:6147:2	O
(	TREANDA.xml:S1:6150:1	O
8	TREANDA.xml:S1:6151:1	O
)	TREANDA.xml:S1:6152:1	O
4	TREANDA.xml:S1:6161:1	O
(	TREANDA.xml:S1:6163:1	O
3	TREANDA.xml:S1:6164:1	O
)	TREANDA.xml:S1:6165:1	O
7	TREANDA.xml:S1:6174:1	O
(	TREANDA.xml:S1:6176:1	O
5	TREANDA.xml:S1:6177:1	O
)	TREANDA.xml:S1:6178:1	O
3	TREANDA.xml:S1:6188:1	O
(	TREANDA.xml:S1:6190:1	O
2	TREANDA.xml:S1:6191:1	O
)	TREANDA.xml:S1:6192:1	O

Pruritus	TREANDA.xml:S1:6206:8	B-AdverseReaction
8	TREANDA.xml:S1:6258:1	O
(	TREANDA.xml:S1:6260:1	O
5	TREANDA.xml:S1:6261:1	O
)	TREANDA.xml:S1:6262:1	O
0	TREANDA.xml:S1:6272:1	O
2	TREANDA.xml:S1:6285:1	O
(	TREANDA.xml:S1:6287:1	O
1	TREANDA.xml:S1:6288:1	O
)	TREANDA.xml:S1:6289:1	O
0	TREANDA.xml:S1:6299:1	O

The	TREANDA.xml:S1:6324:3	O
Grade	TREANDA.xml:S1:6328:5	O
3	TREANDA.xml:S1:6334:1	O
and	TREANDA.xml:S1:6336:3	O
4	TREANDA.xml:S1:6340:1	O
hematology	TREANDA.xml:S1:6342:10	O
laboratory	TREANDA.xml:S1:6353:10	O
test	TREANDA.xml:S1:6364:4	O
values	TREANDA.xml:S1:6369:6	O
by	TREANDA.xml:S1:6376:2	O
treatment	TREANDA.xml:S1:6379:9	O
group	TREANDA.xml:S1:6389:5	O
in	TREANDA.xml:S1:6395:2	O
the	TREANDA.xml:S1:6398:3	O
randomized	TREANDA.xml:S1:6402:10	O
CLL	TREANDA.xml:S1:6413:3	O
clinical	TREANDA.xml:S1:6417:8	O
study	TREANDA.xml:S1:6426:5	O
are	TREANDA.xml:S1:6432:3	O
described	TREANDA.xml:S1:6436:9	O
in	TREANDA.xml:S1:6446:2	O
Table	TREANDA.xml:S1:6449:5	O
2	TREANDA.xml:S1:6455:1	O
.	TREANDA.xml:S1:6456:1	O

These	TREANDA.xml:S1:6458:5	O
findings	TREANDA.xml:S1:6464:8	O
confirm	TREANDA.xml:S1:6473:7	O
the	TREANDA.xml:S1:6481:3	O
myelosuppressive	TREANDA.xml:S1:6485:16	B-AdverseReaction
effects	TREANDA.xml:S1:6502:7	I-AdverseReaction
seen	TREANDA.xml:S1:6510:4	O
in	TREANDA.xml:S1:6515:2	O
patients	TREANDA.xml:S1:6518:8	O
treated	TREANDA.xml:S1:6527:7	O
with	TREANDA.xml:S1:6535:4	O
TREANDA	TREANDA.xml:S1:6540:7	O
.	TREANDA.xml:S1:6547:1	O

Red	TREANDA.xml:S1:6549:3	O
blood	TREANDA.xml:S1:6553:5	O
cell	TREANDA.xml:S1:6559:4	O
transfusions	TREANDA.xml:S1:6564:12	O
were	TREANDA.xml:S1:6577:4	O
administered	TREANDA.xml:S1:6582:12	O
to	TREANDA.xml:S1:6595:2	O
20%	TREANDA.xml:S1:6598:3	O
of	TREANDA.xml:S1:6602:2	O
patients	TREANDA.xml:S1:6605:8	O
receiving	TREANDA.xml:S1:6614:9	O
TREANDA	TREANDA.xml:S1:6624:7	O
compared	TREANDA.xml:S1:6632:8	O
with	TREANDA.xml:S1:6641:4	O
6%	TREANDA.xml:S1:6646:2	O
of	TREANDA.xml:S1:6649:2	O
patients	TREANDA.xml:S1:6652:8	O
receiving	TREANDA.xml:S1:6661:9	O
chlorambucil	TREANDA.xml:S1:6671:12	O
.	TREANDA.xml:S1:6683:1	O

Table	TREANDA.xml:S1:6689:5	O

2	TREANDA.xml:S1:6695:1	O
:	TREANDA.xml:S1:6696:1	O
Incidence	TREANDA.xml:S1:6699:9	O
of	TREANDA.xml:S1:6709:2	O
Hematology	TREANDA.xml:S1:6712:10	O
Laboratory	TREANDA.xml:S1:6723:10	O
Abnormalities	TREANDA.xml:S1:6734:13	O
in	TREANDA.xml:S1:6748:2	O
Patients	TREANDA.xml:S1:6751:8	O
Who	TREANDA.xml:S1:6760:3	O
Received	TREANDA.xml:S1:6764:8	O
TREANDA	TREANDA.xml:S1:6773:7	O
or	TREANDA.xml:S1:6781:2	O
Chlorambucil	TREANDA.xml:S1:6784:12	O
in	TREANDA.xml:S1:6797:2	O
the	TREANDA.xml:S1:6800:3	O
Randomized	TREANDA.xml:S1:6804:10	O
CLL	TREANDA.xml:S1:6815:3	O
Clinical	TREANDA.xml:S1:6819:8	O
Study	TREANDA.xml:S1:6828:5	O

TREANDA	TREANDA.xml:S1:6866:7	O
N	TREANDA.xml:S1:6874:1	O
150	TREANDA.xml:S1:6876:3	O
ChlorambucilN	TREANDA.xml:S1:6883:13	O
141	TREANDA.xml:S1:6897:3	O

Laboratory	TREANDA.xml:S1:6907:10	O
Abnormality	TREANDA.xml:S1:6918:11	O
All	TREANDA.xml:S1:6936:3	O
Gradesn	TREANDA.xml:S1:6940:7	O
(	TREANDA.xml:S1:6948:1	O
)	TREANDA.xml:S1:6950:1	O
Grade	TREANDA.xml:S1:6955:5	O
3	TREANDA.xml:S1:6961:1	O
4	TREANDA.xml:S1:6963:1	O
n	TREANDA.xml:S1:6964:1	O
(	TREANDA.xml:S1:6966:1	O
)	TREANDA.xml:S1:6968:1	O
All	TREANDA.xml:S1:6973:3	O
Gradesn	TREANDA.xml:S1:6977:7	O
(	TREANDA.xml:S1:6985:1	O
)	TREANDA.xml:S1:6987:1	O
Grade	TREANDA.xml:S1:6992:5	O
3	TREANDA.xml:S1:6998:1	O
4	TREANDA.xml:S1:7000:1	O
n	TREANDA.xml:S1:7001:1	O
(	TREANDA.xml:S1:7003:1	O
)	TREANDA.xml:S1:7005:1	O

Hemoglobin	TREANDA.xml:S1:7013:10	B-AdverseReaction
Decreased	TREANDA.xml:S1:7024:9	I-AdverseReaction
134	TREANDA.xml:S1:7042:3	O
(	TREANDA.xml:S1:7046:1	O
89	TREANDA.xml:S1:7047:2	O
)	TREANDA.xml:S1:7049:1	O
20	TREANDA.xml:S1:7057:2	O
(	TREANDA.xml:S1:7060:1	O
13	TREANDA.xml:S1:7061:2	O
)	TREANDA.xml:S1:7063:1	O
115	TREANDA.xml:S1:7071:3	O
(	TREANDA.xml:S1:7075:1	O
82	TREANDA.xml:S1:7076:2	O
)	TREANDA.xml:S1:7078:1	O
12	TREANDA.xml:S1:7086:2	O
(	TREANDA.xml:S1:7089:1	O
9	TREANDA.xml:S1:7090:1	O
)	TREANDA.xml:S1:7091:1	O

Platelets	TREANDA.xml:S1:7103:9	B-AdverseReaction
Decreased	TREANDA.xml:S1:7113:9	I-AdverseReaction
116	TREANDA.xml:S1:7132:3	O
(	TREANDA.xml:S1:7136:1	O
77	TREANDA.xml:S1:7137:2	O
)	TREANDA.xml:S1:7139:1	O
16	TREANDA.xml:S1:7147:2	O
(	TREANDA.xml:S1:7150:1	O
11	TREANDA.xml:S1:7151:2	O
)	TREANDA.xml:S1:7153:1	O
110	TREANDA.xml:S1:7161:3	O
(	TREANDA.xml:S1:7165:1	O
78	TREANDA.xml:S1:7166:2	O
)	TREANDA.xml:S1:7168:1	O
14	TREANDA.xml:S1:7176:2	O
(	TREANDA.xml:S1:7179:1	O
10	TREANDA.xml:S1:7180:2	O
)	TREANDA.xml:S1:7182:1	O

Leukocytes	TREANDA.xml:S1:7193:10	B-AdverseReaction
Decreased	TREANDA.xml:S1:7204:9	I-AdverseReaction
92	TREANDA.xml:S1:7222:2	O
(	TREANDA.xml:S1:7225:1	O
61	TREANDA.xml:S1:7226:2	O
)	TREANDA.xml:S1:7228:1	O
42	TREANDA.xml:S1:7237:2	O
(	TREANDA.xml:S1:7240:1	O
28	TREANDA.xml:S1:7241:2	O
)	TREANDA.xml:S1:7243:1	O
26	TREANDA.xml:S1:7251:2	O
(	TREANDA.xml:S1:7254:1	O
18	TREANDA.xml:S1:7255:2	O
)	TREANDA.xml:S1:7257:1	O
4	TREANDA.xml:S1:7266:1	O
(	TREANDA.xml:S1:7268:1	O
3	TREANDA.xml:S1:7269:1	O
)	TREANDA.xml:S1:7270:1	O

Lymphocytes	TREANDA.xml:S1:7283:11	B-AdverseReaction
Decreased	TREANDA.xml:S1:7295:9	I-AdverseReaction
102	TREANDA.xml:S1:7312:3	O
(	TREANDA.xml:S1:7316:1	O
68	TREANDA.xml:S1:7317:2	O
)	TREANDA.xml:S1:7319:1	O
70	TREANDA.xml:S1:7327:2	O
(	TREANDA.xml:S1:7330:1	O
47	TREANDA.xml:S1:7331:2	O
)	TREANDA.xml:S1:7333:1	O
27	TREANDA.xml:S1:7341:2	O
(	TREANDA.xml:S1:7344:1	O
19	TREANDA.xml:S1:7345:2	O
)	TREANDA.xml:S1:7347:1	O
6	TREANDA.xml:S1:7356:1	O
(	TREANDA.xml:S1:7358:1	O
4	TREANDA.xml:S1:7359:1	O
)	TREANDA.xml:S1:7360:1	O

Neutrophils	TREANDA.xml:S1:7373:11	B-AdverseReaction
Decreased	TREANDA.xml:S1:7385:9	I-AdverseReaction
113	TREANDA.xml:S1:7402:3	O
(	TREANDA.xml:S1:7406:1	O
75	TREANDA.xml:S1:7407:2	O
)	TREANDA.xml:S1:7409:1	O
65	TREANDA.xml:S1:7417:2	O
(	TREANDA.xml:S1:7420:1	O
43	TREANDA.xml:S1:7421:2	O
)	TREANDA.xml:S1:7423:1	O
86	TREANDA.xml:S1:7431:2	O
(	TREANDA.xml:S1:7434:1	O
61	TREANDA.xml:S1:7435:2	O
)	TREANDA.xml:S1:7437:1	O
30	TREANDA.xml:S1:7446:2	O
(	TREANDA.xml:S1:7449:1	O
21	TREANDA.xml:S1:7450:2	O
)	TREANDA.xml:S1:7452:1	O

In	TREANDA.xml:S1:7472:2	O
the	TREANDA.xml:S1:7475:3	O
CLL	TREANDA.xml:S1:7479:3	O
trial	TREANDA.xml:S1:7483:5	O
,	TREANDA.xml:S1:7488:1	O
34%	TREANDA.xml:S1:7490:3	O
of	TREANDA.xml:S1:7494:2	O
patients	TREANDA.xml:S1:7497:8	O
had	TREANDA.xml:S1:7506:3	O
bilirubin	TREANDA.xml:S1:7510:9	B-AdverseReaction
elevations	TREANDA.xml:S1:7520:10	I-AdverseReaction
,	TREANDA.xml:S1:7530:1	O
some	TREANDA.xml:S1:7532:4	O
without	TREANDA.xml:S1:7537:7	B-Negation
associated	TREANDA.xml:S1:7545:10	O
significant	TREANDA.xml:S1:7556:11	B-Severity
elevations	TREANDA.xml:S1:7568:10	B-AdverseReaction
in	TREANDA.xml:S1:7579:2	I-AdverseReaction
AST	TREANDA.xml:S1:7582:3	I-AdverseReaction
and	TREANDA.xml:S1:7586:3	O
ALT	TREANDA.xml:S1:7590:3	I-AdverseReaction
.	TREANDA.xml:S1:7593:1	O

Grade	TREANDA.xml:S1:7596:5	B-Severity
3	TREANDA.xml:S1:7602:1	I-Severity
or	TREANDA.xml:S1:7604:2	O
4	TREANDA.xml:S1:7607:1	I-Severity
increased	TREANDA.xml:S1:7609:9	B-AdverseReaction
bilirubin	TREANDA.xml:S1:7619:9	I-AdverseReaction
occurred	TREANDA.xml:S1:7629:8	O
in	TREANDA.xml:S1:7638:2	O
3%	TREANDA.xml:S1:7641:2	O
of	TREANDA.xml:S1:7644:2	O
patients	TREANDA.xml:S1:7647:8	O
.	TREANDA.xml:S1:7655:1	O

Increases	TREANDA.xml:S1:7658:9	B-AdverseReaction
in	TREANDA.xml:S1:7668:2	I-AdverseReaction
AST	TREANDA.xml:S1:7671:3	I-AdverseReaction
and	TREANDA.xml:S1:7675:3	O
ALT	TREANDA.xml:S1:7679:3	I-AdverseReaction
of	TREANDA.xml:S1:7683:2	O
Grade	TREANDA.xml:S1:7686:5	B-Severity
3	TREANDA.xml:S1:7692:1	I-Severity
or	TREANDA.xml:S1:7694:2	O
4	TREANDA.xml:S1:7697:1	I-Severity
were	TREANDA.xml:S1:7699:4	O
limited	TREANDA.xml:S1:7704:7	O
to	TREANDA.xml:S1:7712:2	O
1%	TREANDA.xml:S1:7715:2	O
and	TREANDA.xml:S1:7718:3	O
3%	TREANDA.xml:S1:7722:2	O
of	TREANDA.xml:S1:7725:2	O
patients	TREANDA.xml:S1:7728:8	O
,	TREANDA.xml:S1:7736:1	O
respectively	TREANDA.xml:S1:7738:12	O
.	TREANDA.xml:S1:7750:1	O

Patients	TREANDA.xml:S1:7753:8	O
treated	TREANDA.xml:S1:7762:7	O
with	TREANDA.xml:S1:7770:4	O
TREANDA	TREANDA.xml:S1:7775:7	O
may	TREANDA.xml:S1:7783:3	B-Factor
also	TREANDA.xml:S1:7787:4	O
have	TREANDA.xml:S1:7792:4	O
changes	TREANDA.xml:S1:7797:7	B-AdverseReaction
in	TREANDA.xml:S1:7805:2	I-AdverseReaction
their	TREANDA.xml:S1:7808:5	O
creatinine	TREANDA.xml:S1:7814:10	I-AdverseReaction
levels	TREANDA.xml:S1:7825:6	I-AdverseReaction
.	TREANDA.xml:S1:7831:1	O

If	TREANDA.xml:S1:7833:2	O
abnormalities	TREANDA.xml:S1:7836:13	O
are	TREANDA.xml:S1:7850:3	O
detected	TREANDA.xml:S1:7854:8	O
,	TREANDA.xml:S1:7862:1	O
monitoring	TREANDA.xml:S1:7864:10	O
of	TREANDA.xml:S1:7875:2	O
these	TREANDA.xml:S1:7878:5	O
parameters	TREANDA.xml:S1:7884:10	O
should	TREANDA.xml:S1:7895:6	O
be	TREANDA.xml:S1:7902:2	O
continued	TREANDA.xml:S1:7905:9	O
to	TREANDA.xml:S1:7915:2	O
ensure	TREANDA.xml:S1:7918:6	O
that	TREANDA.xml:S1:7925:4	O
further	TREANDA.xml:S1:7930:7	O
deterioration	TREANDA.xml:S1:7938:13	O
does	TREANDA.xml:S1:7952:4	O
not	TREANDA.xml:S1:7957:3	O
occur	TREANDA.xml:S1:7961:5	O
.	TREANDA.xml:S1:7966:1	O

Non	TREANDA.xml:S1:7974:3	O

-	TREANDA.xml:S1:7977:1	O
Hodgkin	TREANDA.xml:S1:7978:7	O
Lymphoma	TREANDA.xml:S1:7986:8	O

The	TREANDA.xml:S1:8001:3	O
data	TREANDA.xml:S1:8005:4	O
described	TREANDA.xml:S1:8010:9	O
below	TREANDA.xml:S1:8020:5	O
reflect	TREANDA.xml:S1:8026:7	O
exposure	TREANDA.xml:S1:8034:8	O
to	TREANDA.xml:S1:8043:2	O
TREANDA	TREANDA.xml:S1:8046:7	O
in	TREANDA.xml:S1:8054:2	O
176	TREANDA.xml:S1:8057:3	O
patients	TREANDA.xml:S1:8061:8	O
with	TREANDA.xml:S1:8070:4	O
indolent	TREANDA.xml:S1:8075:8	O
B	TREANDA.xml:S1:8084:1	O
-	TREANDA.xml:S1:8085:1	O
cell	TREANDA.xml:S1:8086:4	O
NHL	TREANDA.xml:S1:8091:3	O
treated	TREANDA.xml:S1:8095:7	O
in	TREANDA.xml:S1:8103:2	O
two	TREANDA.xml:S1:8106:3	O
single	TREANDA.xml:S1:8110:6	O
-	TREANDA.xml:S1:8116:1	O
arm	TREANDA.xml:S1:8117:3	O
studies	TREANDA.xml:S1:8121:7	O
.	TREANDA.xml:S1:8128:1	O

The	TREANDA.xml:S1:8131:3	O
population	TREANDA.xml:S1:8135:10	O
was	TREANDA.xml:S1:8146:3	O
31	TREANDA.xml:S1:8150:2	O
-	TREANDA.xml:S1:8152:1	O
84	TREANDA.xml:S1:8153:2	O
years	TREANDA.xml:S1:8156:5	O
of	TREANDA.xml:S1:8162:2	O
age	TREANDA.xml:S1:8165:3	O
,	TREANDA.xml:S1:8168:1	O
60%	TREANDA.xml:S1:8170:3	O
male	TREANDA.xml:S1:8174:4	O
,	TREANDA.xml:S1:8178:1	O
and	TREANDA.xml:S1:8180:3	O
40%	TREANDA.xml:S1:8184:3	O
female	TREANDA.xml:S1:8188:6	O
.	TREANDA.xml:S1:8194:1	O

The	TREANDA.xml:S1:8197:3	O
race	TREANDA.xml:S1:8201:4	O
distribution	TREANDA.xml:S1:8206:12	O
was	TREANDA.xml:S1:8219:3	O
89%	TREANDA.xml:S1:8223:3	O
White	TREANDA.xml:S1:8227:5	O
,	TREANDA.xml:S1:8232:1	O
7%	TREANDA.xml:S1:8234:2	O
Black	TREANDA.xml:S1:8237:5	O
,	TREANDA.xml:S1:8242:1	O
3%	TREANDA.xml:S1:8244:2	O
Hispanic	TREANDA.xml:S1:8247:8	O
,	TREANDA.xml:S1:8255:1	O
1%	TREANDA.xml:S1:8257:2	O
other	TREANDA.xml:S1:8260:5	O
,	TREANDA.xml:S1:8265:1	O
and	TREANDA.xml:S1:8267:3	O
1%	TREANDA.xml:S1:8272:2	O
Asian	TREANDA.xml:S1:8275:5	O
.	TREANDA.xml:S1:8280:1	O

These	TREANDA.xml:S1:8282:5	O
patients	TREANDA.xml:S1:8288:8	O
received	TREANDA.xml:S1:8297:8	O
TREANDA	TREANDA.xml:S1:8306:7	O
at	TREANDA.xml:S1:8314:2	O
a	TREANDA.xml:S1:8317:1	O
dose	TREANDA.xml:S1:8319:4	O
of	TREANDA.xml:S1:8324:2	O
120	TREANDA.xml:S1:8327:3	O
mg	TREANDA.xml:S1:8331:2	O
m	TREANDA.xml:S1:8334:1	O
2	TREANDA.xml:S1:8337:1	O
intravenously	TREANDA.xml:S1:8340:13	O
on	TREANDA.xml:S1:8354:2	O
Days	TREANDA.xml:S1:8357:4	O
1	TREANDA.xml:S1:8362:1	O
and	TREANDA.xml:S1:8364:3	O
2	TREANDA.xml:S1:8368:1	O
for	TREANDA.xml:S1:8370:3	O
up	TREANDA.xml:S1:8374:2	O
to	TREANDA.xml:S1:8377:2	O
eight	TREANDA.xml:S1:8380:5	O
21	TREANDA.xml:S1:8386:2	O
-	TREANDA.xml:S1:8388:1	O
day	TREANDA.xml:S1:8389:3	O
cycles	TREANDA.xml:S1:8393:6	O
.	TREANDA.xml:S1:8399:1	O

The	TREANDA.xml:S1:8405:3	O
adverse	TREANDA.xml:S1:8409:7	O
reactions	TREANDA.xml:S1:8417:9	O
occurring	TREANDA.xml:S1:8427:9	O
in	TREANDA.xml:S1:8437:2	O
at	TREANDA.xml:S1:8440:2	O
least	TREANDA.xml:S1:8443:5	O
5%	TREANDA.xml:S1:8449:2	O
of	TREANDA.xml:S1:8452:2	O
the	TREANDA.xml:S1:8455:3	O
NHL	TREANDA.xml:S1:8459:3	O
patients	TREANDA.xml:S1:8463:8	O
,	TREANDA.xml:S1:8471:1	O
regardless	TREANDA.xml:S1:8473:10	O
of	TREANDA.xml:S1:8484:2	O
severity	TREANDA.xml:S1:8487:8	O
,	TREANDA.xml:S1:8495:1	O
are	TREANDA.xml:S1:8497:3	O
shown	TREANDA.xml:S1:8501:5	O
in	TREANDA.xml:S1:8507:2	O
Table	TREANDA.xml:S1:8510:5	O
3	TREANDA.xml:S1:8516:1	O
.	TREANDA.xml:S1:8517:1	O

The	TREANDA.xml:S1:8519:3	O
most	TREANDA.xml:S1:8523:4	O
common	TREANDA.xml:S1:8528:6	O
non	TREANDA.xml:S1:8535:3	O
-	TREANDA.xml:S1:8538:1	O
hematologic	TREANDA.xml:S1:8539:11	O
adverse	TREANDA.xml:S1:8551:7	O
reactions	TREANDA.xml:S1:8559:9	O
(	TREANDA.xml:S1:8569:1	O
30%	TREANDA.xml:S1:8572:3	O
)	TREANDA.xml:S1:8575:1	O
were	TREANDA.xml:S1:8577:4	O
nausea	TREANDA.xml:S1:8582:6	B-AdverseReaction
(	TREANDA.xml:S1:8589:1	O
75%	TREANDA.xml:S1:8590:3	O
)	TREANDA.xml:S1:8593:1	O
,	TREANDA.xml:S1:8594:1	O
fatigue	TREANDA.xml:S1:8596:7	B-AdverseReaction
(	TREANDA.xml:S1:8604:1	O
57%	TREANDA.xml:S1:8605:3	O
)	TREANDA.xml:S1:8608:1	O
,	TREANDA.xml:S1:8609:1	O
vomiting	TREANDA.xml:S1:8611:8	B-AdverseReaction
(	TREANDA.xml:S1:8620:1	O
40%	TREANDA.xml:S1:8621:3	O
)	TREANDA.xml:S1:8624:1	O
,	TREANDA.xml:S1:8625:1	O
diarrhea	TREANDA.xml:S1:8627:8	B-AdverseReaction
(	TREANDA.xml:S1:8636:1	O
37%	TREANDA.xml:S1:8637:3	O
)	TREANDA.xml:S1:8640:1	O
and	TREANDA.xml:S1:8642:3	O
pyrexia	TREANDA.xml:S1:8646:7	B-AdverseReaction
(	TREANDA.xml:S1:8654:1	O
34%	TREANDA.xml:S1:8655:3	O
)	TREANDA.xml:S1:8658:1	O
.	TREANDA.xml:S1:8659:1	O

The	TREANDA.xml:S1:8662:3	O
most	TREANDA.xml:S1:8666:4	O
common	TREANDA.xml:S1:8671:6	O
non	TREANDA.xml:S1:8678:3	O
-	TREANDA.xml:S1:8681:1	O
hematologic	TREANDA.xml:S1:8682:11	O
Grade	TREANDA.xml:S1:8694:5	O
3	TREANDA.xml:S1:8700:1	O
or	TREANDA.xml:S1:8702:2	O
4	TREANDA.xml:S1:8705:1	O
adverse	TREANDA.xml:S1:8707:7	O
reactions	TREANDA.xml:S1:8715:9	O
(	TREANDA.xml:S1:8725:1	O
5%	TREANDA.xml:S1:8728:2	O
)	TREANDA.xml:S1:8730:1	O
were	TREANDA.xml:S1:8732:4	O
fatigue	TREANDA.xml:S1:8737:7	B-AdverseReaction
(	TREANDA.xml:S1:8745:1	O
11%	TREANDA.xml:S1:8746:3	O
)	TREANDA.xml:S1:8749:1	O
,	TREANDA.xml:S1:8750:1	O
febrile	TREANDA.xml:S1:8752:7	B-AdverseReaction
neutropenia	TREANDA.xml:S1:8760:11	I-AdverseReaction
(	TREANDA.xml:S1:8772:1	O
6%	TREANDA.xml:S1:8773:2	O
)	TREANDA.xml:S1:8775:1	O
,	TREANDA.xml:S1:8776:1	O
and	TREANDA.xml:S1:8778:3	O
pneumonia	TREANDA.xml:S1:8782:9	B-AdverseReaction
,	TREANDA.xml:S1:8791:1	O
hypokalemia	TREANDA.xml:S1:8793:11	B-AdverseReaction
and	TREANDA.xml:S1:8805:3	O
dehydration	TREANDA.xml:S1:8809:11	B-AdverseReaction
,	TREANDA.xml:S1:8820:1	O
each	TREANDA.xml:S1:8822:4	O
reported	TREANDA.xml:S1:8827:8	O
in	TREANDA.xml:S1:8836:2	O
5%	TREANDA.xml:S1:8839:2	O
of	TREANDA.xml:S1:8842:2	O
patients	TREANDA.xml:S1:8845:8	O
.	TREANDA.xml:S1:8853:1	O

Table	TREANDA.xml:S1:8859:5	O
3	TREANDA.xml:S1:8865:1	O
:	TREANDA.xml:S1:8866:1	O
Non	TREANDA.xml:S1:8868:3	O
-	TREANDA.xml:S1:8871:1	O
Hematologic	TREANDA.xml:S1:8872:11	O
Adverse	TREANDA.xml:S1:8884:7	O
Reactions	TREANDA.xml:S1:8892:9	O
Occurring	TREANDA.xml:S1:8902:9	O
in	TREANDA.xml:S1:8912:2	O
at	TREANDA.xml:S1:8915:2	O
Least	TREANDA.xml:S1:8918:5	O
5%	TREANDA.xml:S1:8924:2	O
of	TREANDA.xml:S1:8927:2	O
NHL	TREANDA.xml:S1:8930:3	O
Patients	TREANDA.xml:S1:8934:8	O
Treated	TREANDA.xml:S1:8943:7	O
with	TREANDA.xml:S1:8951:4	O
TREANDA	TREANDA.xml:S1:8956:7	O
by	TREANDA.xml:S1:8964:2	O
System	TREANDA.xml:S1:8967:6	O
Organ	TREANDA.xml:S1:8974:5	O
Class	TREANDA.xml:S1:8980:5	O
and	TREANDA.xml:S1:8986:3	O
Preferred	TREANDA.xml:S1:8990:9	O
Term	TREANDA.xml:S1:9000:4	O
(	TREANDA.xml:S1:9005:1	O
N	TREANDA.xml:S1:9006:1	O
176	TREANDA.xml:S1:9008:3	O
)	TREANDA.xml:S1:9011:1	O

System	TREANDA.xml:S1:9016:6	O
organ	TREANDA.xml:S1:9023:5	O
class	TREANDA.xml:S1:9029:5	O
Number	TREANDA.xml:S1:9086:6	O
(	TREANDA.xml:S1:9093:1	O
)	TREANDA.xml:S1:9095:1	O
of	TREANDA.xml:S1:9097:2	O
patients	TREANDA.xml:S1:9100:8	O

Preferred	TREANDA.xml:S1:9120:9	O
term	TREANDA.xml:S1:9130:4	O
All	TREANDA.xml:S1:9186:3	O
Grades	TREANDA.xml:S1:9190:6	O
Grade	TREANDA.xml:S1:9204:5	O
3	TREANDA.xml:S1:9210:1	O
4	TREANDA.xml:S1:9212:1	O

Total	TREANDA.xml:S1:9224:5	O
number	TREANDA.xml:S1:9230:6	O
of	TREANDA.xml:S1:9237:2	O
patients	TREANDA.xml:S1:9240:8	O
with	TREANDA.xml:S1:9249:4	O
at	TREANDA.xml:S1:9254:2	O
least	TREANDA.xml:S1:9257:5	O
1	TREANDA.xml:S1:9263:1	O
adverse	TREANDA.xml:S1:9265:7	O
reaction	TREANDA.xml:S1:9273:8	O
176	TREANDA.xml:S1:9294:3	O
(	TREANDA.xml:S1:9298:1	O
100	TREANDA.xml:S1:9299:3	O
)	TREANDA.xml:S1:9302:1	O
94	TREANDA.xml:S1:9312:2	O
(	TREANDA.xml:S1:9315:1	O
53	TREANDA.xml:S1:9316:2	O
)	TREANDA.xml:S1:9318:1	O

Cardiac	TREANDA.xml:S1:9332:7	O
disorders	TREANDA.xml:S1:9340:9	O

Tachycardia	TREANDA.xml:S1:9409:11	B-AdverseReaction
13	TREANDA.xml:S1:9475:2	O
(	TREANDA.xml:S1:9478:1	O
7	TREANDA.xml:S1:9479:1	O
)	TREANDA.xml:S1:9480:1	O
0	TREANDA.xml:S1:9493:1	O

Gastrointestinal	TREANDA.xml:S1:9513:16	O
disorders	TREANDA.xml:S1:9530:9	O

Nausea	TREANDA.xml:S1:9590:6	B-AdverseReaction
132	TREANDA.xml:S1:9656:3	O
(	TREANDA.xml:S1:9660:1	O
75	TREANDA.xml:S1:9661:2	O
)	TREANDA.xml:S1:9663:1	O
7	TREANDA.xml:S1:9674:1	O
(	TREANDA.xml:S1:9676:1	O
4	TREANDA.xml:S1:9677:1	O
)	TREANDA.xml:S1:9678:1	O

Vomiting	TREANDA.xml:S1:9698:8	B-AdverseReaction
71	TREANDA.xml:S1:9764:2	O
(	TREANDA.xml:S1:9767:1	O
40	TREANDA.xml:S1:9768:2	O
)	TREANDA.xml:S1:9770:1	O
5	TREANDA.xml:S1:9782:1	O
(	TREANDA.xml:S1:9784:1	O
3	TREANDA.xml:S1:9785:1	O
)	TREANDA.xml:S1:9786:1	O

Diarrhea	TREANDA.xml:S1:9806:8	B-AdverseReaction
65	TREANDA.xml:S1:9872:2	O
(	TREANDA.xml:S1:9875:1	O
37	TREANDA.xml:S1:9876:2	O
)	TREANDA.xml:S1:9878:1	O
6	TREANDA.xml:S1:9890:1	O
(	TREANDA.xml:S1:9892:1	O
3	TREANDA.xml:S1:9893:1	O
)	TREANDA.xml:S1:9894:1	O

Constipation	TREANDA.xml:S1:9914:12	B-AdverseReaction
51	TREANDA.xml:S1:9980:2	O
(	TREANDA.xml:S1:9983:1	O
29	TREANDA.xml:S1:9984:2	O
)	TREANDA.xml:S1:9986:1	O
1	TREANDA.xml:S1:9998:1	O
(	TREANDA.xml:S1:10000:1	O
1	TREANDA.xml:S1:10002:1	O
)	TREANDA.xml:S1:10003:1	O

Stomatitis	TREANDA.xml:S1:10022:10	B-AdverseReaction
27	TREANDA.xml:S1:10088:2	O
(	TREANDA.xml:S1:10091:1	O
15	TREANDA.xml:S1:10092:2	O
)	TREANDA.xml:S1:10094:1	O
1	TREANDA.xml:S1:10106:1	O
(	TREANDA.xml:S1:10108:1	O
1	TREANDA.xml:S1:10110:1	O
)	TREANDA.xml:S1:10111:1	O

Abdominal	TREANDA.xml:S1:10130:9	B-AdverseReaction
pain	TREANDA.xml:S1:10140:4	I-AdverseReaction
22	TREANDA.xml:S1:10196:2	O
(	TREANDA.xml:S1:10199:1	O
13	TREANDA.xml:S1:10200:2	O
)	TREANDA.xml:S1:10202:1	O
2	TREANDA.xml:S1:10214:1	O
(	TREANDA.xml:S1:10216:1	O
1	TREANDA.xml:S1:10217:1	O
)	TREANDA.xml:S1:10218:1	O

Dyspepsia	TREANDA.xml:S1:10238:9	B-AdverseReaction
20	TREANDA.xml:S1:10304:2	O
(	TREANDA.xml:S1:10307:1	O
11	TREANDA.xml:S1:10308:2	O
)	TREANDA.xml:S1:10310:1	O
0	TREANDA.xml:S1:10322:1	O

Gastroesophageal	TREANDA.xml:S1:10346:16	B-AdverseReaction
reflux	TREANDA.xml:S1:10363:6	I-AdverseReaction
disease	TREANDA.xml:S1:10370:7	I-AdverseReaction
18	TREANDA.xml:S1:10412:2	O
(	TREANDA.xml:S1:10415:1	O
10	TREANDA.xml:S1:10416:2	O
)	TREANDA.xml:S1:10418:1	O
0	TREANDA.xml:S1:10430:1	O

Dry	TREANDA.xml:S1:10454:3	B-AdverseReaction
mouth	TREANDA.xml:S1:10458:5	I-AdverseReaction
15	TREANDA.xml:S1:10520:2	O
(	TREANDA.xml:S1:10523:1	O
9	TREANDA.xml:S1:10524:1	O
)	TREANDA.xml:S1:10525:1	O
1	TREANDA.xml:S1:10538:1	O
(	TREANDA.xml:S1:10540:1	O
1	TREANDA.xml:S1:10542:1	O
)	TREANDA.xml:S1:10543:1	O

Abdominal	TREANDA.xml:S1:10562:9	B-AdverseReaction
pain	TREANDA.xml:S1:10572:4	I-AdverseReaction
upper	TREANDA.xml:S1:10577:5	I-AdverseReaction
8	TREANDA.xml:S1:10628:1	O
(	TREANDA.xml:S1:10630:1	O
5	TREANDA.xml:S1:10631:1	O
)	TREANDA.xml:S1:10632:1	O
0	TREANDA.xml:S1:10646:1	O

Abdominal	TREANDA.xml:S1:10670:9	B-AdverseReaction
distension	TREANDA.xml:S1:10680:10	I-AdverseReaction
8	TREANDA.xml:S1:10736:1	O
(	TREANDA.xml:S1:10738:1	O
5	TREANDA.xml:S1:10739:1	O
)	TREANDA.xml:S1:10740:1	O
0	TREANDA.xml:S1:10754:1	O

General	TREANDA.xml:S1:10774:7	O
disorders	TREANDA.xml:S1:10782:9	O
and	TREANDA.xml:S1:10792:3	O
administration	TREANDA.xml:S1:10796:14	O
site	TREANDA.xml:S1:10811:4	O
conditions	TREANDA.xml:S1:10816:10	O

Fatigue	TREANDA.xml:S1:10851:7	B-AdverseReaction
101	TREANDA.xml:S1:10917:3	O
(	TREANDA.xml:S1:10921:1	O
57	TREANDA.xml:S1:10922:2	O
)	TREANDA.xml:S1:10924:1	O
19	TREANDA.xml:S1:10935:2	O
(	TREANDA.xml:S1:10938:1	O
11	TREANDA.xml:S1:10939:2	O
)	TREANDA.xml:S1:10941:1	O

Pyrexia	TREANDA.xml:S1:10959:7	B-AdverseReaction
59	TREANDA.xml:S1:11025:2	O
(	TREANDA.xml:S1:11028:1	O
34	TREANDA.xml:S1:11029:2	O
)	TREANDA.xml:S1:11031:1	O
3	TREANDA.xml:S1:11043:1	O
(	TREANDA.xml:S1:11045:1	O
2	TREANDA.xml:S1:11046:1	O
)	TREANDA.xml:S1:11047:1	O

Chills	TREANDA.xml:S1:11067:6	B-AdverseReaction
24	TREANDA.xml:S1:11133:2	O
(	TREANDA.xml:S1:11136:1	O
14	TREANDA.xml:S1:11137:2	O
)	TREANDA.xml:S1:11139:1	O
0	TREANDA.xml:S1:11151:1	O

Edema	TREANDA.xml:S1:11175:5	B-AdverseReaction
peripheral	TREANDA.xml:S1:11181:10	I-AdverseReaction
23	TREANDA.xml:S1:11241:2	O
(	TREANDA.xml:S1:11244:1	O
13	TREANDA.xml:S1:11245:2	O
)	TREANDA.xml:S1:11247:1	O
1	TREANDA.xml:S1:11259:1	O
(	TREANDA.xml:S1:11261:1	O
1	TREANDA.xml:S1:11263:1	O
)	TREANDA.xml:S1:11264:1	O

Asthenia	TREANDA.xml:S1:11283:8	B-AdverseReaction
19	TREANDA.xml:S1:11349:2	O
(	TREANDA.xml:S1:11352:1	O
11	TREANDA.xml:S1:11353:2	O
)	TREANDA.xml:S1:11355:1	O
4	TREANDA.xml:S1:11367:1	O
(	TREANDA.xml:S1:11369:1	O
2	TREANDA.xml:S1:11370:1	O
)	TREANDA.xml:S1:11371:1	O

Chest	TREANDA.xml:S1:11391:5	B-AdverseReaction
pain	TREANDA.xml:S1:11397:4	I-AdverseReaction
11	TREANDA.xml:S1:11457:2	O
(	TREANDA.xml:S1:11460:1	O
6	TREANDA.xml:S1:11461:1	O
)	TREANDA.xml:S1:11462:1	O
1	TREANDA.xml:S1:11475:1	O
(	TREANDA.xml:S1:11477:1	O
1	TREANDA.xml:S1:11479:1	O
)	TREANDA.xml:S1:11480:1	O

Infusion	TREANDA.xml:S1:11499:8	B-AdverseReaction
site	TREANDA.xml:S1:11508:4	I-AdverseReaction
pain	TREANDA.xml:S1:11513:4	I-AdverseReaction
11	TREANDA.xml:S1:11565:2	O
(	TREANDA.xml:S1:11568:1	O
6	TREANDA.xml:S1:11569:1	O
)	TREANDA.xml:S1:11570:1	O
0	TREANDA.xml:S1:11583:1	O

Pain	TREANDA.xml:S1:11607:4	B-AdverseReaction
10	TREANDA.xml:S1:11673:2	O
(	TREANDA.xml:S1:11676:1	O
6	TREANDA.xml:S1:11677:1	O
)	TREANDA.xml:S1:11678:1	O
0	TREANDA.xml:S1:11691:1	O

Catheter	TREANDA.xml:S1:11715:8	B-AdverseReaction
site	TREANDA.xml:S1:11724:4	I-AdverseReaction
pain	TREANDA.xml:S1:11729:4	I-AdverseReaction
8	TREANDA.xml:S1:11781:1	O
(	TREANDA.xml:S1:11783:1	O
5	TREANDA.xml:S1:11784:1	O
)	TREANDA.xml:S1:11785:1	O
0	TREANDA.xml:S1:11799:1	O

Infections	TREANDA.xml:S1:11819:10	O
and	TREANDA.xml:S1:11830:3	O
infestations	TREANDA.xml:S1:11834:12	O

Herpes	TREANDA.xml:S1:11896:6	B-AdverseReaction
zoster	TREANDA.xml:S1:11903:6	I-AdverseReaction
18	TREANDA.xml:S1:11962:2	O
(	TREANDA.xml:S1:11965:1	O
10	TREANDA.xml:S1:11966:2	O
)	TREANDA.xml:S1:11968:1	O
5	TREANDA.xml:S1:11980:1	O
(	TREANDA.xml:S1:11982:1	O
3	TREANDA.xml:S1:11983:1	O
)	TREANDA.xml:S1:11984:1	O

Upper	TREANDA.xml:S1:12004:5	B-AdverseReaction
respiratory	TREANDA.xml:S1:12010:11	I-AdverseReaction
tract	TREANDA.xml:S1:12022:5	I-AdverseReaction
infection	TREANDA.xml:S1:12028:9	I-AdverseReaction
18	TREANDA.xml:S1:12070:2	O
(	TREANDA.xml:S1:12073:1	O
10	TREANDA.xml:S1:12074:2	O
)	TREANDA.xml:S1:12076:1	O
0	TREANDA.xml:S1:12088:1	O

Urinary	TREANDA.xml:S1:12112:7	B-AdverseReaction
tract	TREANDA.xml:S1:12120:5	I-AdverseReaction
infection	TREANDA.xml:S1:12126:9	I-AdverseReaction
17	TREANDA.xml:S1:12178:2	O
(	TREANDA.xml:S1:12181:1	O
10	TREANDA.xml:S1:12182:2	O
)	TREANDA.xml:S1:12184:1	O
4	TREANDA.xml:S1:12196:1	O
(	TREANDA.xml:S1:12198:1	O
2	TREANDA.xml:S1:12199:1	O
)	TREANDA.xml:S1:12200:1	O

Sinusitis	TREANDA.xml:S1:12220:9	B-AdverseReaction
15	TREANDA.xml:S1:12286:2	O
(	TREANDA.xml:S1:12289:1	O
9	TREANDA.xml:S1:12290:1	O
)	TREANDA.xml:S1:12291:1	O
0	TREANDA.xml:S1:12304:1	O

Pneumonia	TREANDA.xml:S1:12328:9	B-AdverseReaction
14	TREANDA.xml:S1:12394:2	O
(	TREANDA.xml:S1:12397:1	O
8	TREANDA.xml:S1:12398:1	O
)	TREANDA.xml:S1:12399:1	O
9	TREANDA.xml:S1:12412:1	O
(	TREANDA.xml:S1:12414:1	O
5	TREANDA.xml:S1:12415:1	O
)	TREANDA.xml:S1:12416:1	O

Febrile	TREANDA.xml:S1:12436:7	B-AdverseReaction
neutropenia	TREANDA.xml:S1:12444:11	I-AdverseReaction
11	TREANDA.xml:S1:12502:2	O
(	TREANDA.xml:S1:12505:1	O
6	TREANDA.xml:S1:12506:1	O
)	TREANDA.xml:S1:12507:1	O
11	TREANDA.xml:S1:12520:2	O
(	TREANDA.xml:S1:12523:1	O
6	TREANDA.xml:S1:12524:1	O
)	TREANDA.xml:S1:12525:1	O

Oral	TREANDA.xml:S1:12544:4	B-AdverseReaction
candidiasis	TREANDA.xml:S1:12549:11	I-AdverseReaction
11	TREANDA.xml:S1:12610:2	O
(	TREANDA.xml:S1:12613:1	O
6	TREANDA.xml:S1:12614:1	O
)	TREANDA.xml:S1:12615:1	O
2	TREANDA.xml:S1:12628:1	O
(	TREANDA.xml:S1:12630:1	O
1	TREANDA.xml:S1:12631:1	O
)	TREANDA.xml:S1:12632:1	O

Nasopharyngitis	TREANDA.xml:S1:12652:15	B-AdverseReaction
11	TREANDA.xml:S1:12718:2	O
(	TREANDA.xml:S1:12721:1	O
6	TREANDA.xml:S1:12722:1	O
)	TREANDA.xml:S1:12723:1	O
0	TREANDA.xml:S1:12736:1	O

Investigations	TREANDA.xml:S1:12756:14	O

Weight	TREANDA.xml:S1:12833:6	B-AdverseReaction
decreased	TREANDA.xml:S1:12840:9	I-AdverseReaction
31	TREANDA.xml:S1:12899:2	O
(	TREANDA.xml:S1:12902:1	O
18	TREANDA.xml:S1:12903:2	O
)	TREANDA.xml:S1:12905:1	O
3	TREANDA.xml:S1:12917:1	O
(	TREANDA.xml:S1:12919:1	O
2	TREANDA.xml:S1:12920:1	O
)	TREANDA.xml:S1:12921:1	O

Metabolism	TREANDA.xml:S1:12937:10	O
and	TREANDA.xml:S1:12948:3	O
nutrition	TREANDA.xml:S1:12952:9	O
disorders	TREANDA.xml:S1:12962:9	O

Anorexia	TREANDA.xml:S1:13014:8	B-AdverseReaction
40	TREANDA.xml:S1:13080:2	O
(	TREANDA.xml:S1:13083:1	O
23	TREANDA.xml:S1:13084:2	O
)	TREANDA.xml:S1:13086:1	O
3	TREANDA.xml:S1:13098:1	O
(	TREANDA.xml:S1:13100:1	O
2	TREANDA.xml:S1:13101:1	O
)	TREANDA.xml:S1:13102:1	O

Dehydration	TREANDA.xml:S1:13122:11	B-AdverseReaction
24	TREANDA.xml:S1:13188:2	O
(	TREANDA.xml:S1:13191:1	O
14	TREANDA.xml:S1:13192:2	O
)	TREANDA.xml:S1:13194:1	O
8	TREANDA.xml:S1:13206:1	O
(	TREANDA.xml:S1:13208:1	O
5	TREANDA.xml:S1:13209:1	O
)	TREANDA.xml:S1:13210:1	O

Decreased	TREANDA.xml:S1:13230:9	B-AdverseReaction
appetite	TREANDA.xml:S1:13240:8	I-AdverseReaction
22	TREANDA.xml:S1:13296:2	O
(	TREANDA.xml:S1:13299:1	O
13	TREANDA.xml:S1:13300:2	O
)	TREANDA.xml:S1:13302:1	O
1	TREANDA.xml:S1:13314:1	O
(	TREANDA.xml:S1:13316:1	O
1	TREANDA.xml:S1:13318:1	O
)	TREANDA.xml:S1:13319:1	O

Hypokalemia	TREANDA.xml:S1:13338:11	B-AdverseReaction
15	TREANDA.xml:S1:13404:2	O
(	TREANDA.xml:S1:13407:1	O
9	TREANDA.xml:S1:13408:1	O
)	TREANDA.xml:S1:13409:1	O
9	TREANDA.xml:S1:13422:1	O
(	TREANDA.xml:S1:13424:1	O
5	TREANDA.xml:S1:13425:1	O
)	TREANDA.xml:S1:13426:1	O

Musculoskeletal	TREANDA.xml:S1:13442:15	O
and	TREANDA.xml:S1:13458:3	O
connective	TREANDA.xml:S1:13462:10	O
tissue	TREANDA.xml:S1:13473:6	O
disorders	TREANDA.xml:S1:13480:9	O

Back	TREANDA.xml:S1:13519:4	B-AdverseReaction
pain	TREANDA.xml:S1:13524:4	I-AdverseReaction
25	TREANDA.xml:S1:13585:2	O
(	TREANDA.xml:S1:13588:1	O
14	TREANDA.xml:S1:13589:2	O
)	TREANDA.xml:S1:13591:1	O
5	TREANDA.xml:S1:13603:1	O
(	TREANDA.xml:S1:13605:1	O
3	TREANDA.xml:S1:13606:1	O
)	TREANDA.xml:S1:13607:1	O

Arthralgia	TREANDA.xml:S1:13627:10	B-AdverseReaction
11	TREANDA.xml:S1:13693:2	O
(	TREANDA.xml:S1:13696:1	O
6	TREANDA.xml:S1:13697:1	O
)	TREANDA.xml:S1:13698:1	O
0	TREANDA.xml:S1:13711:1	O

Pain	TREANDA.xml:S1:13735:4	B-AdverseReaction
in	TREANDA.xml:S1:13740:2	I-AdverseReaction
extremity	TREANDA.xml:S1:13743:9	I-AdverseReaction
8	TREANDA.xml:S1:13801:1	O
(	TREANDA.xml:S1:13803:1	O
5	TREANDA.xml:S1:13804:1	O
)	TREANDA.xml:S1:13805:1	O
2	TREANDA.xml:S1:13819:1	O
(	TREANDA.xml:S1:13821:1	O
1	TREANDA.xml:S1:13822:1	O
)	TREANDA.xml:S1:13823:1	O

Bone	TREANDA.xml:S1:13843:4	B-AdverseReaction
pain	TREANDA.xml:S1:13848:4	I-AdverseReaction
8	TREANDA.xml:S1:13909:1	O
(	TREANDA.xml:S1:13911:1	O
5	TREANDA.xml:S1:13912:1	O
)	TREANDA.xml:S1:13913:1	O
0	TREANDA.xml:S1:13927:1	O

Nervous	TREANDA.xml:S1:13947:7	O
system	TREANDA.xml:S1:13955:6	O
disorders	TREANDA.xml:S1:13962:9	O

Headache	TREANDA.xml:S1:14024:8	B-AdverseReaction
36	TREANDA.xml:S1:14090:2	O
(	TREANDA.xml:S1:14093:1	O
21	TREANDA.xml:S1:14094:2	O
)	TREANDA.xml:S1:14096:1	O
0	TREANDA.xml:S1:14108:1	O

Dizziness	TREANDA.xml:S1:14132:9	B-AdverseReaction
25	TREANDA.xml:S1:14198:2	O
(	TREANDA.xml:S1:14201:1	O
14	TREANDA.xml:S1:14202:2	O
)	TREANDA.xml:S1:14204:1	O
0	TREANDA.xml:S1:14216:1	O

Dysgeusia	TREANDA.xml:S1:14240:9	B-AdverseReaction
13	TREANDA.xml:S1:14306:2	O
(	TREANDA.xml:S1:14309:1	O
7	TREANDA.xml:S1:14310:1	O
)	TREANDA.xml:S1:14311:1	O
0	TREANDA.xml:S1:14324:1	O

Psychiatric	TREANDA.xml:S1:14344:11	O
disorders	TREANDA.xml:S1:14356:9	O

Insomnia	TREANDA.xml:S1:14421:8	B-AdverseReaction
23	TREANDA.xml:S1:14487:2	O
(	TREANDA.xml:S1:14490:1	O
13	TREANDA.xml:S1:14491:2	O
)	TREANDA.xml:S1:14493:1	O
0	TREANDA.xml:S1:14505:1	O

Anxiety	TREANDA.xml:S1:14529:7	B-AdverseReaction
14	TREANDA.xml:S1:14595:2	O
(	TREANDA.xml:S1:14598:1	O
8	TREANDA.xml:S1:14599:1	O
)	TREANDA.xml:S1:14600:1	O
1	TREANDA.xml:S1:14613:1	O
(	TREANDA.xml:S1:14615:1	O
1	TREANDA.xml:S1:14617:1	O
)	TREANDA.xml:S1:14618:1	O

Depression	TREANDA.xml:S1:14637:10	B-AdverseReaction
10	TREANDA.xml:S1:14703:2	O
(	TREANDA.xml:S1:14706:1	O
6	TREANDA.xml:S1:14707:1	O
)	TREANDA.xml:S1:14708:1	O
0	TREANDA.xml:S1:14721:1	O

Respiratory	TREANDA.xml:S1:14741:11	O
,	TREANDA.xml:S1:14752:1	O
thoracic	TREANDA.xml:S1:14754:8	O
and	TREANDA.xml:S1:14763:3	O
mediastinal	TREANDA.xml:S1:14767:11	O
disorders	TREANDA.xml:S1:14779:9	O

Cough	TREANDA.xml:S1:14818:5	B-AdverseReaction
38	TREANDA.xml:S1:14884:2	O
(	TREANDA.xml:S1:14887:1	O
22	TREANDA.xml:S1:14888:2	O
)	TREANDA.xml:S1:14890:1	O
1	TREANDA.xml:S1:14902:1	O
(	TREANDA.xml:S1:14904:1	O
1	TREANDA.xml:S1:14906:1	O
)	TREANDA.xml:S1:14907:1	O

Dyspnea	TREANDA.xml:S1:14926:7	B-AdverseReaction
28	TREANDA.xml:S1:14992:2	O
(	TREANDA.xml:S1:14995:1	O
16	TREANDA.xml:S1:14996:2	O
)	TREANDA.xml:S1:14998:1	O
3	TREANDA.xml:S1:15010:1	O
(	TREANDA.xml:S1:15012:1	O
2	TREANDA.xml:S1:15013:1	O
)	TREANDA.xml:S1:15014:1	O

Pharyngolaryngeal	TREANDA.xml:S1:15034:17	B-AdverseReaction
pain	TREANDA.xml:S1:15052:4	I-AdverseReaction
14	TREANDA.xml:S1:15100:2	O
(	TREANDA.xml:S1:15103:1	O
8	TREANDA.xml:S1:15104:1	O
)	TREANDA.xml:S1:15105:1	O
1	TREANDA.xml:S1:15118:1	O
(	TREANDA.xml:S1:15120:1	O
1	TREANDA.xml:S1:15122:1	O
)	TREANDA.xml:S1:15123:1	O

Wheezing	TREANDA.xml:S1:15142:8	B-AdverseReaction
8	TREANDA.xml:S1:15208:1	O
(	TREANDA.xml:S1:15210:1	O
5	TREANDA.xml:S1:15211:1	O
)	TREANDA.xml:S1:15212:1	O
0	TREANDA.xml:S1:15226:1	O

Nasal	TREANDA.xml:S1:15250:5	B-AdverseReaction
congestion	TREANDA.xml:S1:15256:10	I-AdverseReaction
8	TREANDA.xml:S1:15316:1	O
(	TREANDA.xml:S1:15318:1	O
5	TREANDA.xml:S1:15319:1	O
)	TREANDA.xml:S1:15320:1	O
0	TREANDA.xml:S1:15334:1	O

Skin	TREANDA.xml:S1:15354:4	O
and	TREANDA.xml:S1:15359:3	O
subcutaneous	TREANDA.xml:S1:15363:12	O
tissue	TREANDA.xml:S1:15376:6	O
disorders	TREANDA.xml:S1:15383:9	O

Rash	TREANDA.xml:S1:15431:4	B-AdverseReaction
28	TREANDA.xml:S1:15497:2	O
(	TREANDA.xml:S1:15500:1	O
16	TREANDA.xml:S1:15501:2	O
)	TREANDA.xml:S1:15503:1	O
1	TREANDA.xml:S1:15515:1	O
(	TREANDA.xml:S1:15517:1	O
1	TREANDA.xml:S1:15519:1	O
)	TREANDA.xml:S1:15520:1	O

Pruritus	TREANDA.xml:S1:15539:8	B-AdverseReaction
11	TREANDA.xml:S1:15605:2	O
(	TREANDA.xml:S1:15608:1	O
6	TREANDA.xml:S1:15609:1	O
)	TREANDA.xml:S1:15610:1	O
0	TREANDA.xml:S1:15623:1	O

Dry	TREANDA.xml:S1:15647:3	B-AdverseReaction
skin	TREANDA.xml:S1:15651:4	I-AdverseReaction
9	TREANDA.xml:S1:15713:1	O
(	TREANDA.xml:S1:15715:1	O
5	TREANDA.xml:S1:15716:1	O
)	TREANDA.xml:S1:15717:1	O
0	TREANDA.xml:S1:15731:1	O

Night	TREANDA.xml:S1:15755:5	B-AdverseReaction
sweats	TREANDA.xml:S1:15761:6	I-AdverseReaction
9	TREANDA.xml:S1:15821:1	O
(	TREANDA.xml:S1:15823:1	O
5	TREANDA.xml:S1:15824:1	O
)	TREANDA.xml:S1:15825:1	O
0	TREANDA.xml:S1:15839:1	O

Hyperhidrosis	TREANDA.xml:S1:15863:13	B-AdverseReaction
8	TREANDA.xml:S1:15929:1	O
(	TREANDA.xml:S1:15931:1	O
5	TREANDA.xml:S1:15932:1	O
)	TREANDA.xml:S1:15933:1	O
0	TREANDA.xml:S1:15947:1	O

Vascular	TREANDA.xml:S1:15967:8	O
disorders	TREANDA.xml:S1:15976:9	O

Hypotension	TREANDA.xml:S1:16044:11	B-AdverseReaction
10	TREANDA.xml:S1:16110:2	O
(	TREANDA.xml:S1:16113:1	O
6	TREANDA.xml:S1:16114:1	O
)	TREANDA.xml:S1:16115:1	O
2	TREANDA.xml:S1:16128:1	O
(	TREANDA.xml:S1:16130:1	O
1	TREANDA.xml:S1:16131:1	O
)	TREANDA.xml:S1:16132:1	O

Patients	TREANDA.xml:S1:16149:8	O
may	TREANDA.xml:S1:16158:3	O
have	TREANDA.xml:S1:16162:4	O
reported	TREANDA.xml:S1:16167:8	O
more	TREANDA.xml:S1:16176:4	O
than	TREANDA.xml:S1:16181:4	O
1	TREANDA.xml:S1:16186:1	O
adverse	TREANDA.xml:S1:16188:7	O
reaction	TREANDA.xml:S1:16196:8	O
.	TREANDA.xml:S1:16204:1	O
NOTE	TREANDA.xml:S1:16205:4	O
:	TREANDA.xml:S1:16209:1	O
Patients	TREANDA.xml:S1:16211:8	O
counted	TREANDA.xml:S1:16220:7	O
only	TREANDA.xml:S1:16228:4	O
once	TREANDA.xml:S1:16233:4	O
in	TREANDA.xml:S1:16238:2	O
each	TREANDA.xml:S1:16241:4	O
preferred	TREANDA.xml:S1:16246:9	O
term	TREANDA.xml:S1:16256:4	O
category	TREANDA.xml:S1:16261:8	O
and	TREANDA.xml:S1:16270:3	O
once	TREANDA.xml:S1:16274:4	O
in	TREANDA.xml:S1:16279:2	O
each	TREANDA.xml:S1:16282:4	O
system	TREANDA.xml:S1:16287:6	O
organ	TREANDA.xml:S1:16294:5	O
class	TREANDA.xml:S1:16300:5	O
category	TREANDA.xml:S1:16306:8	O
.	TREANDA.xml:S1:16314:1	O

Hematologic	TREANDA.xml:S1:16329:11	B-AdverseReaction
toxicities	TREANDA.xml:S1:16341:10	I-AdverseReaction
,	TREANDA.xml:S1:16351:1	O
based	TREANDA.xml:S1:16353:5	O
on	TREANDA.xml:S1:16359:2	O
laboratory	TREANDA.xml:S1:16362:10	O
values	TREANDA.xml:S1:16373:6	O
and	TREANDA.xml:S1:16380:3	O
CTC	TREANDA.xml:S1:16384:3	O
grade	TREANDA.xml:S1:16388:5	O
,	TREANDA.xml:S1:16393:1	O
in	TREANDA.xml:S1:16395:2	O
NHL	TREANDA.xml:S1:16398:3	O
patients	TREANDA.xml:S1:16402:8	O
treated	TREANDA.xml:S1:16411:7	O
in	TREANDA.xml:S1:16419:2	O
both	TREANDA.xml:S1:16422:4	O
single	TREANDA.xml:S1:16427:6	O
arm	TREANDA.xml:S1:16434:3	O
studies	TREANDA.xml:S1:16438:7	O
combined	TREANDA.xml:S1:16446:8	O
are	TREANDA.xml:S1:16455:3	O
described	TREANDA.xml:S1:16459:9	O
in	TREANDA.xml:S1:16469:2	O
Table	TREANDA.xml:S1:16472:5	O
4	TREANDA.xml:S1:16478:1	O
.	TREANDA.xml:S1:16479:1	O

Clinically	TREANDA.xml:S1:16482:10	O
important	TREANDA.xml:S1:16493:9	O
chemistry	TREANDA.xml:S1:16503:9	O
laboratory	TREANDA.xml:S1:16513:10	O
values	TREANDA.xml:S1:16524:6	O
that	TREANDA.xml:S1:16531:4	O
were	TREANDA.xml:S1:16536:4	O
new	TREANDA.xml:S1:16541:3	O
or	TREANDA.xml:S1:16545:2	O
worsened	TREANDA.xml:S1:16548:8	O
from	TREANDA.xml:S1:16557:4	O
baseline	TREANDA.xml:S1:16562:8	O
and	TREANDA.xml:S1:16571:3	O
occurred	TREANDA.xml:S1:16575:8	O
in	TREANDA.xml:S1:16584:2	O
1%	TREANDA.xml:S1:16588:2	O
of	TREANDA.xml:S1:16591:2	O
patients	TREANDA.xml:S1:16594:8	O
at	TREANDA.xml:S1:16603:2	O
Grade	TREANDA.xml:S1:16606:5	O
3	TREANDA.xml:S1:16612:1	O
or	TREANDA.xml:S1:16614:2	O
4	TREANDA.xml:S1:16617:1	O
,	TREANDA.xml:S1:16618:1	O
in	TREANDA.xml:S1:16621:2	O
NHL	TREANDA.xml:S1:16624:3	O
patients	TREANDA.xml:S1:16628:8	O
treated	TREANDA.xml:S1:16637:7	O
in	TREANDA.xml:S1:16645:2	O
both	TREANDA.xml:S1:16648:4	O
single	TREANDA.xml:S1:16653:6	O
arm	TREANDA.xml:S1:16660:3	O
studies	TREANDA.xml:S1:16664:7	O
combined	TREANDA.xml:S1:16672:8	O
were	TREANDA.xml:S1:16681:4	O
hyperglycemia	TREANDA.xml:S1:16686:13	B-AdverseReaction
(	TREANDA.xml:S1:16700:1	O
3%	TREANDA.xml:S1:16701:2	O
)	TREANDA.xml:S1:16703:1	O
,	TREANDA.xml:S1:16704:1	O
elevated	TREANDA.xml:S1:16706:8	B-AdverseReaction
creatinine	TREANDA.xml:S1:16715:10	I-AdverseReaction
(	TREANDA.xml:S1:16726:1	O
2%	TREANDA.xml:S1:16727:2	O
)	TREANDA.xml:S1:16729:1	O
,	TREANDA.xml:S1:16730:1	O
hyponatremia	TREANDA.xml:S1:16732:12	B-AdverseReaction
(	TREANDA.xml:S1:16745:1	O
2%	TREANDA.xml:S1:16746:2	O
)	TREANDA.xml:S1:16748:1	O
,	TREANDA.xml:S1:16749:1	O
and	TREANDA.xml:S1:16751:3	O
hypocalcemia	TREANDA.xml:S1:16755:12	B-AdverseReaction
(	TREANDA.xml:S1:16768:1	O
2%	TREANDA.xml:S1:16769:2	O
)	TREANDA.xml:S1:16771:1	O
.	TREANDA.xml:S1:16772:1	O

Table	TREANDA.xml:S1:16778:5	O

4	TREANDA.xml:S1:16784:1	O
:	TREANDA.xml:S1:16785:1	O
Incidence	TREANDA.xml:S1:16788:9	O
of	TREANDA.xml:S1:16798:2	O
Hematology	TREANDA.xml:S1:16801:10	O
Laboratory	TREANDA.xml:S1:16812:10	O
Abnormalities	TREANDA.xml:S1:16823:13	O
in	TREANDA.xml:S1:16837:2	O
Patients	TREANDA.xml:S1:16840:8	O
Who	TREANDA.xml:S1:16849:3	O
Received	TREANDA.xml:S1:16853:8	O
TREANDA	TREANDA.xml:S1:16862:7	O
in	TREANDA.xml:S1:16870:2	O
the	TREANDA.xml:S1:16873:3	O
NHL	TREANDA.xml:S1:16877:3	O
Studies	TREANDA.xml:S1:16881:7	O

Percent	TREANDA.xml:S1:16917:7	O
of	TREANDA.xml:S1:16925:2	O
patients	TREANDA.xml:S1:16928:8	O

Hematology	TREANDA.xml:S1:16943:10	O
variable	TREANDA.xml:S1:16954:8	O
All	TREANDA.xml:S1:16968:3	O
Grades	TREANDA.xml:S1:16972:6	O
Grades	TREANDA.xml:S1:16983:6	O
3	TREANDA.xml:S1:16990:1	O
4	TREANDA.xml:S1:16992:1	O

Lymphocytes	TREANDA.xml:S1:17001:11	B-AdverseReaction
Decreased	TREANDA.xml:S1:17013:9	I-AdverseReaction
99	TREANDA.xml:S1:17026:2	O
94	TREANDA.xml:S1:17041:2	O

Leukocytes	TREANDA.xml:S1:17059:10	B-AdverseReaction
Decreased	TREANDA.xml:S1:17070:9	I-AdverseReaction
94	TREANDA.xml:S1:17084:2	O
56	TREANDA.xml:S1:17099:2	O

Hemoglobin	TREANDA.xml:S1:17117:10	B-AdverseReaction
Decreased	TREANDA.xml:S1:17128:9	I-AdverseReaction
88	TREANDA.xml:S1:17142:2	O
11	TREANDA.xml:S1:17157:2	O

Neutrophils	TREANDA.xml:S1:17175:11	B-AdverseReaction
Decreased	TREANDA.xml:S1:17187:9	I-AdverseReaction
86	TREANDA.xml:S1:17200:2	O
60	TREANDA.xml:S1:17215:2	O

Platelets	TREANDA.xml:S1:17233:9	B-AdverseReaction
Decreased	TREANDA.xml:S1:17243:9	I-AdverseReaction
86	TREANDA.xml:S1:17258:2	O
25	TREANDA.xml:S1:17273:2	O

In	TREANDA.xml:S1:17298:2	O
both	TREANDA.xml:S1:17301:4	O
studies	TREANDA.xml:S1:17306:7	O
,	TREANDA.xml:S1:17313:1	O
serious	TREANDA.xml:S1:17315:7	O
adverse	TREANDA.xml:S1:17323:7	O
reactions	TREANDA.xml:S1:17331:9	O
,	TREANDA.xml:S1:17340:1	O
regardless	TREANDA.xml:S1:17342:10	O
of	TREANDA.xml:S1:17353:2	O
causality	TREANDA.xml:S1:17356:9	O
,	TREANDA.xml:S1:17365:1	O
were	TREANDA.xml:S1:17367:4	O
reported	TREANDA.xml:S1:17372:8	O
in	TREANDA.xml:S1:17381:2	O
37%	TREANDA.xml:S1:17384:3	O
of	TREANDA.xml:S1:17388:2	O
patients	TREANDA.xml:S1:17391:8	O
receiving	TREANDA.xml:S1:17400:9	O
TREANDA	TREANDA.xml:S1:17410:7	O
.	TREANDA.xml:S1:17417:1	O

The	TREANDA.xml:S1:17420:3	O
most	TREANDA.xml:S1:17424:4	O
common	TREANDA.xml:S1:17429:6	O
serious	TREANDA.xml:S1:17436:7	O
adverse	TREANDA.xml:S1:17444:7	O
reactions	TREANDA.xml:S1:17452:9	O
occurring	TREANDA.xml:S1:17462:9	O
in	TREANDA.xml:S1:17472:2	O
5%	TREANDA.xml:S1:17477:2	O
of	TREANDA.xml:S1:17480:2	O
patients	TREANDA.xml:S1:17483:8	O
were	TREANDA.xml:S1:17492:4	O
febrile	TREANDA.xml:S1:17497:7	B-AdverseReaction
neutropenia	TREANDA.xml:S1:17505:11	I-AdverseReaction
and	TREANDA.xml:S1:17517:3	O
pneumonia	TREANDA.xml:S1:17521:9	B-AdverseReaction
.	TREANDA.xml:S1:17530:1	O

Other	TREANDA.xml:S1:17533:5	O
important	TREANDA.xml:S1:17539:9	O
serious	TREANDA.xml:S1:17549:7	O
adverse	TREANDA.xml:S1:17557:7	O
reactions	TREANDA.xml:S1:17565:9	O
reported	TREANDA.xml:S1:17575:8	O
in	TREANDA.xml:S1:17584:2	O
clinical	TREANDA.xml:S1:17587:8	O
trials	TREANDA.xml:S1:17596:6	O
and	TREANDA.xml:S1:17603:3	O
or	TREANDA.xml:S1:17607:2	O
postmarketing	TREANDA.xml:S1:17610:13	O
experience	TREANDA.xml:S1:17624:10	O
were	TREANDA.xml:S1:17635:4	O
acute	TREANDA.xml:S1:17640:5	B-AdverseReaction
renal	TREANDA.xml:S1:17646:5	I-AdverseReaction
failure	TREANDA.xml:S1:17652:7	I-AdverseReaction
,	TREANDA.xml:S1:17659:1	O
cardiac	TREANDA.xml:S1:17661:7	B-AdverseReaction
failure	TREANDA.xml:S1:17669:7	I-AdverseReaction
,	TREANDA.xml:S1:17676:1	O
hypersensitivity	TREANDA.xml:S1:17678:16	B-AdverseReaction
,	TREANDA.xml:S1:17694:1	O
skin	TREANDA.xml:S1:17696:4	B-AdverseReaction
reactions	TREANDA.xml:S1:17701:9	I-AdverseReaction
,	TREANDA.xml:S1:17710:1	O
pulmonary	TREANDA.xml:S1:17712:9	B-AdverseReaction
fibrosis	TREANDA.xml:S1:17722:8	I-AdverseReaction
,	TREANDA.xml:S1:17730:1	O
and	TREANDA.xml:S1:17732:3	O
myelodysplastic	TREANDA.xml:S1:17736:15	B-AdverseReaction
syndrome	TREANDA.xml:S1:17752:8	I-AdverseReaction
.	TREANDA.xml:S1:17760:1	O

Serious	TREANDA.xml:S1:17766:7	O

drug	TREANDA.xml:S1:17774:4	O
-	TREANDA.xml:S1:17778:1	O
related	TREANDA.xml:S1:17779:7	O
adverse	TREANDA.xml:S1:17787:7	O
reactions	TREANDA.xml:S1:17795:9	O
reported	TREANDA.xml:S1:17805:8	O
in	TREANDA.xml:S1:17814:2	O
clinical	TREANDA.xml:S1:17817:8	O
trials	TREANDA.xml:S1:17826:6	O
included	TREANDA.xml:S1:17833:8	O
myelosuppression	TREANDA.xml:S1:17842:16	B-AdverseReaction
,	TREANDA.xml:S1:17858:1	O
infection	TREANDA.xml:S1:17860:9	B-AdverseReaction
,	TREANDA.xml:S1:17869:1	O
pneumonia	TREANDA.xml:S1:17871:9	B-AdverseReaction
,	TREANDA.xml:S1:17880:1	O
tumor	TREANDA.xml:S1:17882:5	B-AdverseReaction
lysis	TREANDA.xml:S1:17888:5	I-AdverseReaction
syndrome	TREANDA.xml:S1:17894:8	I-AdverseReaction
and	TREANDA.xml:S1:17903:3	O
infusion	TREANDA.xml:S1:17907:8	B-AdverseReaction
reactions	TREANDA.xml:S1:17916:9	I-AdverseReaction
[	TREANDA.xml:S1:17927:1	O
see	TREANDA.xml:S1:17928:3	O
Warnings	TREANDA.xml:S1:17933:8	O
and	TREANDA.xml:S1:17942:3	O
Precautions	TREANDA.xml:S1:17946:11	O
(	TREANDA.xml:S1:17959:1	O
5	TREANDA.xml:S1:17962:1	O
)]	TREANDA.xml:S1:17965:2	O
.	TREANDA.xml:S1:17969:1	O

Adverse	TREANDA.xml:S1:17971:7	O
reactions	TREANDA.xml:S1:17979:9	O
occurring	TREANDA.xml:S1:17989:9	O
less	TREANDA.xml:S1:17999:4	O
frequently	TREANDA.xml:S1:18004:10	O
but	TREANDA.xml:S1:18015:3	O
possibly	TREANDA.xml:S1:18019:8	B-Factor
related	TREANDA.xml:S1:18028:7	O
to	TREANDA.xml:S1:18036:2	O
TREANDA	TREANDA.xml:S1:18039:7	O
treatment	TREANDA.xml:S1:18047:9	O
were	TREANDA.xml:S1:18057:4	O
hemolysis	TREANDA.xml:S1:18062:9	B-AdverseReaction
,	TREANDA.xml:S1:18071:1	O
dysgeusia	TREANDA.xml:S1:18073:9	B-AdverseReaction
taste	TREANDA.xml:S1:18083:5	B-AdverseReaction
disorder	TREANDA.xml:S1:18089:8	I-AdverseReaction
,	TREANDA.xml:S1:18097:1	O
atypical	TREANDA.xml:S1:18099:8	B-AdverseReaction
pneumonia	TREANDA.xml:S1:18108:9	I-AdverseReaction
,	TREANDA.xml:S1:18117:1	O
sepsis	TREANDA.xml:S1:18119:6	B-AdverseReaction
,	TREANDA.xml:S1:18125:1	O
herpes	TREANDA.xml:S1:18127:6	B-AdverseReaction
zoster	TREANDA.xml:S1:18134:6	I-AdverseReaction
,	TREANDA.xml:S1:18140:1	O
erythema	TREANDA.xml:S1:18142:8	B-AdverseReaction
,	TREANDA.xml:S1:18150:1	O
dermatitis	TREANDA.xml:S1:18152:10	B-AdverseReaction
,	TREANDA.xml:S1:18162:1	O
and	TREANDA.xml:S1:18164:3	O
skin	TREANDA.xml:S1:18168:4	B-AdverseReaction
necrosis	TREANDA.xml:S1:18173:8	I-AdverseReaction
.	TREANDA.xml:S1:18181:1	O

6.2	TREANDA.xml:S1:18190:3	O
Postmarketing	TREANDA.xml:S1:18194:13	O
Experience	TREANDA.xml:S1:18208:10	O

The	TREANDA.xml:S1:18222:3	O
following	TREANDA.xml:S1:18226:9	O
adverse	TREANDA.xml:S1:18236:7	O
reactions	TREANDA.xml:S1:18244:9	O
have	TREANDA.xml:S1:18254:4	O
been	TREANDA.xml:S1:18259:4	O
identified	TREANDA.xml:S1:18264:10	O
during	TREANDA.xml:S1:18275:6	O
post	TREANDA.xml:S1:18282:4	O
-	TREANDA.xml:S1:18286:1	O
approval	TREANDA.xml:S1:18287:8	O
use	TREANDA.xml:S1:18296:3	O
of	TREANDA.xml:S1:18300:2	O
TREANDA	TREANDA.xml:S1:18303:7	O
.	TREANDA.xml:S1:18310:1	O

Because	TREANDA.xml:S1:18313:7	O
these	TREANDA.xml:S1:18321:5	O
reactions	TREANDA.xml:S1:18327:9	O
are	TREANDA.xml:S1:18337:3	O
reported	TREANDA.xml:S1:18341:8	O
voluntarily	TREANDA.xml:S1:18350:11	O
from	TREANDA.xml:S1:18362:4	O
a	TREANDA.xml:S1:18367:1	O
population	TREANDA.xml:S1:18369:10	O
of	TREANDA.xml:S1:18380:2	O
uncertain	TREANDA.xml:S1:18383:9	O
size	TREANDA.xml:S1:18393:4	O
,	TREANDA.xml:S1:18397:1	O
it	TREANDA.xml:S1:18399:2	O
is	TREANDA.xml:S1:18402:2	O
not	TREANDA.xml:S1:18405:3	O
always	TREANDA.xml:S1:18409:6	O
possible	TREANDA.xml:S1:18416:8	O
to	TREANDA.xml:S1:18425:2	O
reliably	TREANDA.xml:S1:18428:8	O
estimate	TREANDA.xml:S1:18437:8	O
their	TREANDA.xml:S1:18446:5	O
frequency	TREANDA.xml:S1:18452:9	O
or	TREANDA.xml:S1:18462:2	O
establish	TREANDA.xml:S1:18465:9	O
a	TREANDA.xml:S1:18475:1	O
causal	TREANDA.xml:S1:18477:6	O
relationship	TREANDA.xml:S1:18484:12	O
to	TREANDA.xml:S1:18497:2	O
drug	TREANDA.xml:S1:18500:4	O
exposure	TREANDA.xml:S1:18505:8	O
:	TREANDA.xml:S1:18513:1	O
anaphylaxis	TREANDA.xml:S1:18515:11	B-AdverseReaction
;	TREANDA.xml:S1:18526:1	O
and	TREANDA.xml:S1:18528:3	O
injection	TREANDA.xml:S1:18532:9	B-AdverseReaction
or	TREANDA.xml:S1:18542:2	O
infusion	TREANDA.xml:S1:18545:8	B-AdverseReaction
site	TREANDA.xml:S1:18554:4	I-AdverseReaction
reactions	TREANDA.xml:S1:18559:9	I-AdverseReaction
including	TREANDA.xml:S1:18569:9	O
phlebitis	TREANDA.xml:S1:18579:9	I-AdverseReaction
,	TREANDA.xml:S1:18588:1	O
pruritus	TREANDA.xml:S1:18590:8	I-AdverseReaction
,	TREANDA.xml:S1:18598:1	O
irritation	TREANDA.xml:S1:18600:10	I-AdverseReaction
,	TREANDA.xml:S1:18610:1	O
pain	TREANDA.xml:S1:18612:4	I-AdverseReaction
,	TREANDA.xml:S1:18616:1	O
and	TREANDA.xml:S1:18618:3	O
swelling	TREANDA.xml:S1:18622:8	I-AdverseReaction
;	TREANDA.xml:S1:18630:1	O
pneumocystis	TREANDA.xml:S1:18632:12	B-AdverseReaction
jiroveci	TREANDA.xml:S1:18645:8	I-AdverseReaction
pneumonia	TREANDA.xml:S1:18654:9	I-AdverseReaction
and	TREANDA.xml:S1:18664:3	O
pneumonitis	TREANDA.xml:S1:18668:11	B-AdverseReaction
.	TREANDA.xml:S1:18679:1	O

Skin	TREANDA.xml:S1:18685:4	B-AdverseReaction
reactions	TREANDA.xml:S1:18690:9	I-AdverseReaction
including	TREANDA.xml:S1:18700:9	O
SJS	TREANDA.xml:S1:18710:3	B-AdverseReaction
and	TREANDA.xml:S1:18714:3	O
TEN	TREANDA.xml:S1:18718:3	B-AdverseReaction
have	TREANDA.xml:S1:18722:4	O
occurred	TREANDA.xml:S1:18727:8	O
when	TREANDA.xml:S1:18736:4	O
TREANDA	TREANDA.xml:S1:18741:7	O
was	TREANDA.xml:S1:18749:3	O
administered	TREANDA.xml:S1:18753:12	O
concomitantly	TREANDA.xml:S1:18766:13	O
with	TREANDA.xml:S1:18780:4	O
allopurinol	TREANDA.xml:S1:18785:11	O
and	TREANDA.xml:S1:18797:3	O
other	TREANDA.xml:S1:18801:5	O
medications	TREANDA.xml:S1:18807:11	O
known	TREANDA.xml:S1:18819:5	O
to	TREANDA.xml:S1:18825:2	O
cause	TREANDA.xml:S1:18828:5	O
these	TREANDA.xml:S1:18834:5	O
syndromes	TREANDA.xml:S1:18840:9	O
.	TREANDA.xml:S1:18849:1	O

[	TREANDA.xml:S1:18854:1	O
see	TREANDA.xml:S1:18855:3	O
Warnings	TREANDA.xml:S1:18860:8	O
and	TREANDA.xml:S1:18869:3	O
Precautions	TREANDA.xml:S1:18873:11	O
(	TREANDA.xml:S1:18886:1	O
5.5	TREANDA.xml:S1:18889:3	O
)]	TREANDA.xml:S1:18894:2	O
5	TREANDA.xml:S2:4:1	O
WARNINGS	TREANDA.xml:S2:6:8	O
AND	TREANDA.xml:S2:15:3	O
PRECAUTIONS	TREANDA.xml:S2:19:11	O

EXCERPT	TREANDA.xml:S2:37:7	O
:	TREANDA.xml:S2:44:1	O
Myelosuppression	TREANDA.xml:S2:54:16	B-AdverseReaction
:	TREANDA.xml:S2:70:1	O
Delay	TREANDA.xml:S2:73:5	O
or	TREANDA.xml:S2:79:2	O
reduce	TREANDA.xml:S2:82:6	O
dose	TREANDA.xml:S2:89:4	O
.	TREANDA.xml:S2:93:1	O

Restart	TREANDA.xml:S2:95:7	O
treatment	TREANDA.xml:S2:103:9	O
based	TREANDA.xml:S2:113:5	O
on	TREANDA.xml:S2:119:2	O
ANC	TREANDA.xml:S2:122:3	O
and	TREANDA.xml:S2:126:3	O
platelet	TREANDA.xml:S2:130:8	O
count	TREANDA.xml:S2:139:5	O
recovery	TREANDA.xml:S2:145:8	O
.	TREANDA.xml:S2:153:1	O

(	TREANDA.xml:S2:155:1	O
2.2	TREANDA.xml:S2:158:3	O
)	TREANDA.xml:S2:163:1	O
Complications	TREANDA.xml:S2:165:13	O
of	TREANDA.xml:S2:179:2	O
myelosuppression	TREANDA.xml:S2:182:16	B-AdverseReaction
may	TREANDA.xml:S2:199:3	B-Factor
lead	TREANDA.xml:S2:203:4	O
to	TREANDA.xml:S2:208:2	O
death	TREANDA.xml:S2:211:5	B-AdverseReaction
.	TREANDA.xml:S2:216:1	O

(	TREANDA.xml:S2:218:1	O
5.1	TREANDA.xml:S2:221:3	O
)	TREANDA.xml:S2:226:1	O

Infections	TREANDA.xml:S2:235:10	B-AdverseReaction
:	TREANDA.xml:S2:245:1	O
Monitor	TREANDA.xml:S2:248:7	O
for	TREANDA.xml:S2:256:3	O
fever	TREANDA.xml:S2:260:5	O
and	TREANDA.xml:S2:266:3	O
other	TREANDA.xml:S2:270:5	O
signs	TREANDA.xml:S2:276:5	O
of	TREANDA.xml:S2:282:2	O
infection	TREANDA.xml:S2:285:9	O
and	TREANDA.xml:S2:295:3	O
treat	TREANDA.xml:S2:299:5	O
promptly	TREANDA.xml:S2:305:8	O
.	TREANDA.xml:S2:313:1	O

(	TREANDA.xml:S2:315:1	O
5.2	TREANDA.xml:S2:318:3	O
)	TREANDA.xml:S2:323:1	O

Anaphylaxis	TREANDA.xml:S2:332:11	B-AdverseReaction
and	TREANDA.xml:S2:344:3	O
Infusion	TREANDA.xml:S2:348:8	B-AdverseReaction
Reactions	TREANDA.xml:S2:357:9	I-AdverseReaction
:	TREANDA.xml:S2:366:1	O
Severe	TREANDA.xml:S2:368:6	O
and	TREANDA.xml:S2:375:3	O
anaphylactic	TREANDA.xml:S2:379:12	B-AdverseReaction
reactions	TREANDA.xml:S2:392:9	I-AdverseReaction
have	TREANDA.xml:S2:402:4	O
occurred	TREANDA.xml:S2:407:8	O
;	TREANDA.xml:S2:415:1	O
monitor	TREANDA.xml:S2:417:7	O
clinically	TREANDA.xml:S2:425:10	O
and	TREANDA.xml:S2:436:3	O
discontinue	TREANDA.xml:S2:440:11	O
TREANDA	TREANDA.xml:S2:452:7	O
.	TREANDA.xml:S2:459:1	O

Pre	TREANDA.xml:S2:461:3	O
-	TREANDA.xml:S2:464:1	O
medicate	TREANDA.xml:S2:465:8	O
in	TREANDA.xml:S2:474:2	O
subsequent	TREANDA.xml:S2:477:10	O
cycles	TREANDA.xml:S2:488:6	O
for	TREANDA.xml:S2:495:3	O
milder	TREANDA.xml:S2:499:6	O
reactions	TREANDA.xml:S2:506:9	O
.	TREANDA.xml:S2:515:1	O

(	TREANDA.xml:S2:517:1	O
5.3	TREANDA.xml:S2:520:3	O
)	TREANDA.xml:S2:525:1	O

Tumor	TREANDA.xml:S2:534:5	B-AdverseReaction
Lysis	TREANDA.xml:S2:540:5	I-AdverseReaction
Syndrome	TREANDA.xml:S2:546:8	I-AdverseReaction
:	TREANDA.xml:S2:554:1	O
Acute	TREANDA.xml:S2:557:5	B-AdverseReaction
renal	TREANDA.xml:S2:563:5	I-AdverseReaction
failure	TREANDA.xml:S2:569:7	I-AdverseReaction
and	TREANDA.xml:S2:577:3	O
death	TREANDA.xml:S2:581:5	B-AdverseReaction
;	TREANDA.xml:S2:586:1	O
anticipate	TREANDA.xml:S2:588:10	O
and	TREANDA.xml:S2:599:3	O
use	TREANDA.xml:S2:603:3	O
supportive	TREANDA.xml:S2:607:10	O
measures	TREANDA.xml:S2:618:8	O
.	TREANDA.xml:S2:626:1	O

(	TREANDA.xml:S2:628:1	O
5.4	TREANDA.xml:S2:631:3	O
)	TREANDA.xml:S2:636:1	O

Skin	TREANDA.xml:S2:645:4	B-AdverseReaction
Reactions	TREANDA.xml:S2:650:9	I-AdverseReaction
:	TREANDA.xml:S2:659:1	O
Discontinue	TREANDA.xml:S2:662:11	O
for	TREANDA.xml:S2:674:3	O
severe	TREANDA.xml:S2:678:6	O
skin	TREANDA.xml:S2:685:4	O
reactions	TREANDA.xml:S2:690:9	O
.	TREANDA.xml:S2:699:1	O

Cases	TREANDA.xml:S2:701:5	O
of	TREANDA.xml:S2:707:2	O
SJS	TREANDA.xml:S2:710:3	B-AdverseReaction
and	TREANDA.xml:S2:714:3	O
TEN	TREANDA.xml:S2:718:3	B-AdverseReaction
,	TREANDA.xml:S2:721:1	O
some	TREANDA.xml:S2:723:4	O
fatal	TREANDA.xml:S2:728:5	B-AdverseReaction
,	TREANDA.xml:S2:733:1	O
have	TREANDA.xml:S2:735:4	O
been	TREANDA.xml:S2:740:4	O
reported	TREANDA.xml:S2:745:8	O
when	TREANDA.xml:S2:754:4	O
TREANDA	TREANDA.xml:S2:759:7	O
was	TREANDA.xml:S2:767:3	O
administered	TREANDA.xml:S2:771:12	O
concomitantly	TREANDA.xml:S2:784:13	O
with	TREANDA.xml:S2:798:4	O
allopurinol	TREANDA.xml:S2:803:11	O
and	TREANDA.xml:S2:815:3	O
other	TREANDA.xml:S2:819:5	O
medications	TREANDA.xml:S2:825:11	O
known	TREANDA.xml:S2:837:5	O
to	TREANDA.xml:S2:843:2	O
cause	TREANDA.xml:S2:846:5	O
these	TREANDA.xml:S2:852:5	O
syndromes	TREANDA.xml:S2:858:9	O
.	TREANDA.xml:S2:867:1	O

(	TREANDA.xml:S2:869:1	O
5.5	TREANDA.xml:S2:872:3	O
)	TREANDA.xml:S2:877:1	O

Other	TREANDA.xml:S2:886:5	O
Malignancies	TREANDA.xml:S2:892:12	B-AdverseReaction
:	TREANDA.xml:S2:904:1	O
Pre	TREANDA.xml:S2:906:3	B-AdverseReaction
-	TREANDA.xml:S2:909:1	I-AdverseReaction
malignant	TREANDA.xml:S2:910:9	I-AdverseReaction
and	TREANDA.xml:S2:920:3	O
malignant	TREANDA.xml:S2:924:9	B-AdverseReaction
diseases	TREANDA.xml:S2:934:8	I-AdverseReaction
have	TREANDA.xml:S2:943:4	O
been	TREANDA.xml:S2:948:4	O
reported	TREANDA.xml:S2:953:8	O
.	TREANDA.xml:S2:961:1	O

(	TREANDA.xml:S2:963:1	O
5.6	TREANDA.xml:S2:966:3	O
)	TREANDA.xml:S2:971:1	O

Extravasation	TREANDA.xml:S2:980:13	B-AdverseReaction
:	TREANDA.xml:S2:993:1	O
Assure	TREANDA.xml:S2:995:6	O
good	TREANDA.xml:S2:1002:4	O
venous	TREANDA.xml:S2:1007:6	O
access	TREANDA.xml:S2:1014:6	O
and	TREANDA.xml:S2:1021:3	O
monitor	TREANDA.xml:S2:1025:7	O
infusion	TREANDA.xml:S2:1033:8	O
site	TREANDA.xml:S2:1042:4	O
during	TREANDA.xml:S2:1047:6	O
and	TREANDA.xml:S2:1054:3	O
after	TREANDA.xml:S2:1058:5	O
administration	TREANDA.xml:S2:1064:14	O
.	TREANDA.xml:S2:1078:1	O

(	TREANDA.xml:S2:1080:1	O
5.7	TREANDA.xml:S2:1083:3	O
)	TREANDA.xml:S2:1088:1	O

Embryo	TREANDA.xml:S2:1097:6	B-AdverseReaction
-	TREANDA.xml:S2:1103:1	I-AdverseReaction
fetal	TREANDA.xml:S2:1104:5	I-AdverseReaction
toxicity	TREANDA.xml:S2:1110:8	I-AdverseReaction
:	TREANDA.xml:S2:1118:1	O
Fetal	TREANDA.xml:S2:1121:5	B-AdverseReaction
harm	TREANDA.xml:S2:1127:4	I-AdverseReaction
can	TREANDA.xml:S2:1132:3	B-Factor
occur	TREANDA.xml:S2:1136:5	O
when	TREANDA.xml:S2:1142:4	O
administered	TREANDA.xml:S2:1147:12	O
to	TREANDA.xml:S2:1160:2	O
a	TREANDA.xml:S2:1163:1	O
pregnant	TREANDA.xml:S2:1165:8	O
woman	TREANDA.xml:S2:1174:5	O
.	TREANDA.xml:S2:1179:1	O

Women	TREANDA.xml:S2:1181:5	O
should	TREANDA.xml:S2:1187:6	O
be	TREANDA.xml:S2:1194:2	O
advised	TREANDA.xml:S2:1197:7	O
to	TREANDA.xml:S2:1205:2	O
avoid	TREANDA.xml:S2:1208:5	O
becoming	TREANDA.xml:S2:1214:8	O
pregnant	TREANDA.xml:S2:1223:8	O
when	TREANDA.xml:S2:1232:4	O
receiving	TREANDA.xml:S2:1237:9	O
TREANDA	TREANDA.xml:S2:1247:7	O
.	TREANDA.xml:S2:1254:1	O

(	TREANDA.xml:S2:1256:1	O
5.8	TREANDA.xml:S2:1259:3	O
,	TREANDA.xml:S2:1264:1	O
8.1	TREANDA.xml:S2:1267:3	O
)	TREANDA.xml:S2:1272:1	O

5.1	TREANDA.xml:S2:1286:3	O

Myelosuppression	TREANDA.xml:S2:1291:16	O

TREANDA	TREANDA.xml:S2:1313:7	O

caused	TREANDA.xml:S2:1321:6	O
severe	TREANDA.xml:S2:1328:6	B-Severity
myelosuppression	TREANDA.xml:S2:1335:16	B-AdverseReaction
(	TREANDA.xml:S2:1352:1	O
Grade	TREANDA.xml:S2:1353:5	B-Severity
3	TREANDA.xml:S2:1359:1	I-Severity
-	TREANDA.xml:S2:1360:1	I-Severity
4	TREANDA.xml:S2:1361:1	I-Severity
)	TREANDA.xml:S2:1362:1	O
in	TREANDA.xml:S2:1364:2	O
98%	TREANDA.xml:S2:1367:3	O
of	TREANDA.xml:S2:1371:2	O
patients	TREANDA.xml:S2:1374:8	O
in	TREANDA.xml:S2:1383:2	O
the	TREANDA.xml:S2:1386:3	O
two	TREANDA.xml:S2:1390:3	O
NHL	TREANDA.xml:S2:1394:3	O
studies	TREANDA.xml:S2:1398:7	O
(	TREANDA.xml:S2:1406:1	O
see	TREANDA.xml:S2:1407:3	O
Table	TREANDA.xml:S2:1411:5	O
4	TREANDA.xml:S2:1417:1	O
)	TREANDA.xml:S2:1418:1	O
.	TREANDA.xml:S2:1419:1	O

Three	TREANDA.xml:S2:1421:5	O
patients	TREANDA.xml:S2:1427:8	O
(	TREANDA.xml:S2:1436:1	O
2%	TREANDA.xml:S2:1437:2	O
)	TREANDA.xml:S2:1439:1	O
died	TREANDA.xml:S2:1441:4	B-AdverseReaction
from	TREANDA.xml:S2:1446:4	O
myelosuppression	TREANDA.xml:S2:1451:16	B-AdverseReaction
-	TREANDA.xml:S2:1467:1	I-AdverseReaction
related	TREANDA.xml:S2:1468:7	I-AdverseReaction
adverse	TREANDA.xml:S2:1476:7	I-AdverseReaction
reactions	TREANDA.xml:S2:1484:9	I-AdverseReaction
;	TREANDA.xml:S2:1493:1	O
one	TREANDA.xml:S2:1495:3	O
each	TREANDA.xml:S2:1499:4	O
from	TREANDA.xml:S2:1504:4	O
neutropenic	TREANDA.xml:S2:1509:11	B-AdverseReaction
sepsis	TREANDA.xml:S2:1521:6	I-AdverseReaction
,	TREANDA.xml:S2:1527:1	O
diffuse	TREANDA.xml:S2:1529:7	B-AdverseReaction
alveolar	TREANDA.xml:S2:1537:8	I-AdverseReaction
hemorrhage	TREANDA.xml:S2:1546:10	I-AdverseReaction
with	TREANDA.xml:S2:1557:4	O
Grade	TREANDA.xml:S2:1562:5	B-Severity
3	TREANDA.xml:S2:1568:1	O
thrombocytopenia	TREANDA.xml:S2:1570:16	B-AdverseReaction
,	TREANDA.xml:S2:1586:1	O
and	TREANDA.xml:S2:1588:3	O
pneumonia	TREANDA.xml:S2:1592:9	B-AdverseReaction
from	TREANDA.xml:S2:1602:4	O
an	TREANDA.xml:S2:1607:2	O
opportunistic	TREANDA.xml:S2:1610:13	B-AdverseReaction
infection	TREANDA.xml:S2:1624:9	I-AdverseReaction
(	TREANDA.xml:S2:1634:1	O
CMV	TREANDA.xml:S2:1635:3	I-AdverseReaction
)	TREANDA.xml:S2:1638:1	O
.	TREANDA.xml:S2:1639:1	O

In	TREANDA.xml:S2:1645:2	O
the	TREANDA.xml:S2:1648:3	O
event	TREANDA.xml:S2:1652:5	O
of	TREANDA.xml:S2:1658:2	O
treatment	TREANDA.xml:S2:1661:9	O
-	TREANDA.xml:S2:1670:1	O
related	TREANDA.xml:S2:1671:7	O
myelosuppression	TREANDA.xml:S2:1679:16	O
,	TREANDA.xml:S2:1695:1	O
monitor	TREANDA.xml:S2:1697:7	O
leukocytes	TREANDA.xml:S2:1705:10	O
,	TREANDA.xml:S2:1715:1	O
platelets	TREANDA.xml:S2:1717:9	O
,	TREANDA.xml:S2:1726:1	O
hemoglobin	TREANDA.xml:S2:1728:10	O
(	TREANDA.xml:S2:1739:1	O
Hgb	TREANDA.xml:S2:1740:3	O
)	TREANDA.xml:S2:1743:1	O
,	TREANDA.xml:S2:1744:1	O
and	TREANDA.xml:S2:1746:3	O
neutrophils	TREANDA.xml:S2:1750:11	O
frequently	TREANDA.xml:S2:1762:10	O
.	TREANDA.xml:S2:1772:1	O

In	TREANDA.xml:S2:1774:2	O
the	TREANDA.xml:S2:1777:3	O
clinical	TREANDA.xml:S2:1781:8	O
trials	TREANDA.xml:S2:1790:6	O
,	TREANDA.xml:S2:1796:1	O
blood	TREANDA.xml:S2:1798:5	O
counts	TREANDA.xml:S2:1804:6	O
were	TREANDA.xml:S2:1811:4	O
monitored	TREANDA.xml:S2:1816:9	O
every	TREANDA.xml:S2:1826:5	O
week	TREANDA.xml:S2:1832:4	O
initially	TREANDA.xml:S2:1837:9	O
.	TREANDA.xml:S2:1846:1	O

Hematologic	TREANDA.xml:S2:1848:11	O
nadirs	TREANDA.xml:S2:1860:6	O
were	TREANDA.xml:S2:1867:4	O
observed	TREANDA.xml:S2:1872:8	O
predominantly	TREANDA.xml:S2:1881:13	O
in	TREANDA.xml:S2:1895:2	O
the	TREANDA.xml:S2:1898:3	O
third	TREANDA.xml:S2:1902:5	O
week	TREANDA.xml:S2:1908:4	O
of	TREANDA.xml:S2:1913:2	O
therapy	TREANDA.xml:S2:1916:7	O
.	TREANDA.xml:S2:1923:1	O

Myelosuppression	TREANDA.xml:S2:1925:16	O
may	TREANDA.xml:S2:1942:3	O
require	TREANDA.xml:S2:1946:7	O
dose	TREANDA.xml:S2:1954:4	O
delays	TREANDA.xml:S2:1959:6	O
and	TREANDA.xml:S2:1966:3	O
or	TREANDA.xml:S2:1970:2	O
subsequent	TREANDA.xml:S2:1973:10	O
dose	TREANDA.xml:S2:1984:4	O
reductions	TREANDA.xml:S2:1989:10	O
if	TREANDA.xml:S2:2000:2	O
recovery	TREANDA.xml:S2:2003:8	O
to	TREANDA.xml:S2:2012:2	O
the	TREANDA.xml:S2:2015:3	O
recommended	TREANDA.xml:S2:2019:11	O
values	TREANDA.xml:S2:2031:6	O
has	TREANDA.xml:S2:2038:3	O
not	TREANDA.xml:S2:2042:3	O
occurred	TREANDA.xml:S2:2046:8	O
by	TREANDA.xml:S2:2055:2	O
the	TREANDA.xml:S2:2058:3	O
first	TREANDA.xml:S2:2062:5	O
day	TREANDA.xml:S2:2068:3	O
of	TREANDA.xml:S2:2072:2	O
the	TREANDA.xml:S2:2075:3	O
next	TREANDA.xml:S2:2079:4	O
scheduled	TREANDA.xml:S2:2084:9	O
cycle	TREANDA.xml:S2:2094:5	O
.	TREANDA.xml:S2:2099:1	O

Prior	TREANDA.xml:S2:2101:5	O
to	TREANDA.xml:S2:2107:2	O
the	TREANDA.xml:S2:2110:3	O
initiation	TREANDA.xml:S2:2114:10	O
of	TREANDA.xml:S2:2125:2	O
the	TREANDA.xml:S2:2128:3	O
next	TREANDA.xml:S2:2132:4	O
cycle	TREANDA.xml:S2:2137:5	O
of	TREANDA.xml:S2:2143:2	O
therapy	TREANDA.xml:S2:2146:7	O
,	TREANDA.xml:S2:2153:1	O
the	TREANDA.xml:S2:2155:3	O
ANC	TREANDA.xml:S2:2159:3	O
should	TREANDA.xml:S2:2163:6	O
be	TREANDA.xml:S2:2170:2	O
1	TREANDA.xml:S2:2176:1	O
x	TREANDA.xml:S2:2178:1	O
10	TREANDA.xml:S2:2180:2	O
9	TREANDA.xml:S2:2184:1	O
L	TREANDA.xml:S2:2188:1	O
and	TREANDA.xml:S2:2190:3	O
the	TREANDA.xml:S2:2194:3	O
platelet	TREANDA.xml:S2:2198:8	O
count	TREANDA.xml:S2:2207:5	O
should	TREANDA.xml:S2:2213:6	O
be	TREANDA.xml:S2:2220:2	O
75	TREANDA.xml:S2:2226:2	O
x	TREANDA.xml:S2:2229:1	O
10	TREANDA.xml:S2:2231:2	O
9	TREANDA.xml:S2:2235:1	O
L.	TREANDA.xml:S2:2239:2	O

[	TREANDA.xml:S2:2242:1	O
see	TREANDA.xml:S2:2243:3	O
Dosage	TREANDA.xml:S2:2248:6	O
and	TREANDA.xml:S2:2255:3	O
Administration	TREANDA.xml:S2:2259:14	O
(	TREANDA.xml:S2:2275:1	O
2.2	TREANDA.xml:S2:2278:3	O
)	TREANDA.xml:S2:2283:1	O
and	TREANDA.xml:S2:2285:3	O
(	TREANDA.xml:S2:2289:1	O
2.3	TREANDA.xml:S2:2292:3	O
)]	TREANDA.xml:S2:2297:2	O

5.2	TREANDA.xml:S2:2309:3	O
Infections	TREANDA.xml:S2:2314:10	O

Infection	TREANDA.xml:S2:2330:9	B-AdverseReaction
,	TREANDA.xml:S2:2339:1	O
including	TREANDA.xml:S2:2341:9	O
pneumonia	TREANDA.xml:S2:2351:9	B-AdverseReaction
,	TREANDA.xml:S2:2360:1	O
sepsis	TREANDA.xml:S2:2362:6	B-AdverseReaction
,	TREANDA.xml:S2:2368:1	O
septic	TREANDA.xml:S2:2370:6	B-AdverseReaction
shock	TREANDA.xml:S2:2377:5	I-AdverseReaction
,	TREANDA.xml:S2:2382:1	O
and	TREANDA.xml:S2:2384:3	O
death	TREANDA.xml:S2:2388:5	B-AdverseReaction
have	TREANDA.xml:S2:2394:4	O
occurred	TREANDA.xml:S2:2399:8	O
in	TREANDA.xml:S2:2408:2	O
adult	TREANDA.xml:S2:2411:5	O
and	TREANDA.xml:S2:2417:3	O
pediatric	TREANDA.xml:S2:2421:9	O
patients	TREANDA.xml:S2:2431:8	O
in	TREANDA.xml:S2:2440:2	O
clinical	TREANDA.xml:S2:2443:8	O
trials	TREANDA.xml:S2:2452:6	O
and	TREANDA.xml:S2:2459:3	O
in	TREANDA.xml:S2:2463:2	O
postmarketing	TREANDA.xml:S2:2466:13	O
reports	TREANDA.xml:S2:2480:7	O
.	TREANDA.xml:S2:2487:1	O

Patients	TREANDA.xml:S2:2489:8	O
with	TREANDA.xml:S2:2498:4	O
myelosuppression	TREANDA.xml:S2:2503:16	B-AdverseReaction
following	TREANDA.xml:S2:2520:9	O
treatment	TREANDA.xml:S2:2530:9	O
with	TREANDA.xml:S2:2540:4	O
TREANDA	TREANDA.xml:S2:2545:7	O
are	TREANDA.xml:S2:2553:3	O
more	TREANDA.xml:S2:2557:4	O
susceptible	TREANDA.xml:S2:2562:11	B-Factor
to	TREANDA.xml:S2:2574:2	O
infections	TREANDA.xml:S2:2577:10	B-AdverseReaction
.	TREANDA.xml:S2:2587:1	O

Advise	TREANDA.xml:S2:2589:6	O
patients	TREANDA.xml:S2:2596:8	O
with	TREANDA.xml:S2:2605:4	O
myelosuppression	TREANDA.xml:S2:2610:16	O
following	TREANDA.xml:S2:2627:9	O
TREANDA	TREANDA.xml:S2:2637:7	O
treatment	TREANDA.xml:S2:2645:9	O
to	TREANDA.xml:S2:2655:2	O
contact	TREANDA.xml:S2:2658:7	O
a	TREANDA.xml:S2:2666:1	O
physician	TREANDA.xml:S2:2668:9	O
if	TREANDA.xml:S2:2678:2	O
they	TREANDA.xml:S2:2681:4	O
have	TREANDA.xml:S2:2686:4	O
symptoms	TREANDA.xml:S2:2691:8	O
or	TREANDA.xml:S2:2700:2	O
signs	TREANDA.xml:S2:2703:5	O
of	TREANDA.xml:S2:2709:2	O
infection	TREANDA.xml:S2:2712:9	O
.	TREANDA.xml:S2:2721:1	O

5.3	TREANDA.xml:S2:2730:3	O
Anaphylaxis	TREANDA.xml:S2:2735:11	O
and	TREANDA.xml:S2:2747:3	O
Infusion	TREANDA.xml:S2:2751:8	O
Reactions	TREANDA.xml:S2:2760:9	O

Infusion	TREANDA.xml:S2:2775:8	B-AdverseReaction
reactions	TREANDA.xml:S2:2784:9	I-AdverseReaction
to	TREANDA.xml:S2:2794:2	O
TREANDA	TREANDA.xml:S2:2797:7	O
have	TREANDA.xml:S2:2805:4	O
occurred	TREANDA.xml:S2:2810:8	O
commonly	TREANDA.xml:S2:2819:8	O
in	TREANDA.xml:S2:2828:2	O
clinical	TREANDA.xml:S2:2831:8	O
trials	TREANDA.xml:S2:2840:6	O
.	TREANDA.xml:S2:2846:1	O

Symptoms	TREANDA.xml:S2:2848:8	O
include	TREANDA.xml:S2:2857:7	O
fever	TREANDA.xml:S2:2865:5	B-AdverseReaction
,	TREANDA.xml:S2:2870:1	O
chills	TREANDA.xml:S2:2872:6	B-AdverseReaction
,	TREANDA.xml:S2:2878:1	O
pruritus	TREANDA.xml:S2:2880:8	B-AdverseReaction
and	TREANDA.xml:S2:2889:3	O
rash	TREANDA.xml:S2:2893:4	B-AdverseReaction
.	TREANDA.xml:S2:2897:1	O

In	TREANDA.xml:S2:2899:2	O
rare	TREANDA.xml:S2:2902:4	O
instances	TREANDA.xml:S2:2907:9	O
severe	TREANDA.xml:S2:2917:6	B-Severity
anaphylactic	TREANDA.xml:S2:2924:12	B-AdverseReaction
and	TREANDA.xml:S2:2937:3	O
anaphylactoid	TREANDA.xml:S2:2941:13	B-AdverseReaction
reactions	TREANDA.xml:S2:2955:9	I-AdverseReaction
have	TREANDA.xml:S2:2965:4	O
occurred	TREANDA.xml:S2:2970:8	O
,	TREANDA.xml:S2:2978:1	O
particularly	TREANDA.xml:S2:2980:12	O
in	TREANDA.xml:S2:2993:2	O
the	TREANDA.xml:S2:2996:3	O
second	TREANDA.xml:S2:3000:6	O
and	TREANDA.xml:S2:3007:3	O
subsequent	TREANDA.xml:S2:3011:10	O
cycles	TREANDA.xml:S2:3022:6	O
of	TREANDA.xml:S2:3029:2	O
therapy	TREANDA.xml:S2:3032:7	O
.	TREANDA.xml:S2:3039:1	O

Monitor	TREANDA.xml:S2:3041:7	O
clinically	TREANDA.xml:S2:3049:10	O
and	TREANDA.xml:S2:3060:3	O
discontinue	TREANDA.xml:S2:3064:11	O
drug	TREANDA.xml:S2:3076:4	O
for	TREANDA.xml:S2:3081:3	O
severe	TREANDA.xml:S2:3085:6	O
reactions	TREANDA.xml:S2:3092:9	O
.	TREANDA.xml:S2:3101:1	O

Ask	TREANDA.xml:S2:3103:3	O
patients	TREANDA.xml:S2:3107:8	O
about	TREANDA.xml:S2:3116:5	O
symptoms	TREANDA.xml:S2:3122:8	O
suggestive	TREANDA.xml:S2:3131:10	O
of	TREANDA.xml:S2:3142:2	O
infusion	TREANDA.xml:S2:3145:8	O
reactions	TREANDA.xml:S2:3154:9	O
after	TREANDA.xml:S2:3164:5	O
their	TREANDA.xml:S2:3170:5	O
first	TREANDA.xml:S2:3176:5	O
cycle	TREANDA.xml:S2:3182:5	O
of	TREANDA.xml:S2:3188:2	O
therapy	TREANDA.xml:S2:3191:7	O
.	TREANDA.xml:S2:3198:1	O

Patients	TREANDA.xml:S2:3200:8	O
who	TREANDA.xml:S2:3209:3	O
experience	TREANDA.xml:S2:3213:10	O
Grade	TREANDA.xml:S2:3224:5	O
3	TREANDA.xml:S2:3230:1	O
or	TREANDA.xml:S2:3232:2	O
worse	TREANDA.xml:S2:3235:5	O
allergic	TREANDA.xml:S2:3241:8	O
-	TREANDA.xml:S2:3249:1	O
type	TREANDA.xml:S2:3250:4	O
reactions	TREANDA.xml:S2:3255:9	O
should	TREANDA.xml:S2:3265:6	O
not	TREANDA.xml:S2:3272:3	O
be	TREANDA.xml:S2:3276:2	O
rechallenged	TREANDA.xml:S2:3279:12	O
.	TREANDA.xml:S2:3291:1	O

Consider	TREANDA.xml:S2:3293:8	O
measures	TREANDA.xml:S2:3302:8	O
to	TREANDA.xml:S2:3311:2	O
prevent	TREANDA.xml:S2:3314:7	O
severe	TREANDA.xml:S2:3322:6	O
reactions	TREANDA.xml:S2:3329:9	O
,	TREANDA.xml:S2:3338:1	O
including	TREANDA.xml:S2:3340:9	O
antihistamines	TREANDA.xml:S2:3350:14	O
,	TREANDA.xml:S2:3364:1	O
antipyretics	TREANDA.xml:S2:3366:12	O
and	TREANDA.xml:S2:3379:3	O
corticosteroids	TREANDA.xml:S2:3383:15	O
in	TREANDA.xml:S2:3399:2	O
subsequent	TREANDA.xml:S2:3402:10	O
cycles	TREANDA.xml:S2:3413:6	O
in	TREANDA.xml:S2:3420:2	O
patients	TREANDA.xml:S2:3423:8	O
who	TREANDA.xml:S2:3432:3	O
have	TREANDA.xml:S2:3436:4	O
experienced	TREANDA.xml:S2:3441:11	O
Grade	TREANDA.xml:S2:3453:5	O
1	TREANDA.xml:S2:3459:1	O
or	TREANDA.xml:S2:3461:2	O
2	TREANDA.xml:S2:3464:1	O
infusion	TREANDA.xml:S2:3466:8	O
reactions	TREANDA.xml:S2:3475:9	O
.	TREANDA.xml:S2:3484:1	O

Discontinue	TREANDA.xml:S2:3486:11	O
TREANDA	TREANDA.xml:S2:3498:7	O
for	TREANDA.xml:S2:3506:3	O
patients	TREANDA.xml:S2:3510:8	O
with	TREANDA.xml:S2:3519:4	O
Grade	TREANDA.xml:S2:3524:5	O
4	TREANDA.xml:S2:3530:1	O
infusion	TREANDA.xml:S2:3532:8	O
reactions	TREANDA.xml:S2:3541:9	O
.	TREANDA.xml:S2:3550:1	O

Consider	TREANDA.xml:S2:3552:8	O
discontinuation	TREANDA.xml:S2:3561:15	O
for	TREANDA.xml:S2:3577:3	O
Grade	TREANDA.xml:S2:3581:5	O
3	TREANDA.xml:S2:3587:1	O
infusions	TREANDA.xml:S2:3589:9	O
reactions	TREANDA.xml:S2:3599:9	O
as	TREANDA.xml:S2:3609:2	O
clinically	TREANDA.xml:S2:3612:10	O
appropriate	TREANDA.xml:S2:3623:11	O
considering	TREANDA.xml:S2:3635:11	O
individual	TREANDA.xml:S2:3647:10	O
benefits	TREANDA.xml:S2:3658:8	O
,	TREANDA.xml:S2:3666:1	O
risks	TREANDA.xml:S2:3668:5	O
,	TREANDA.xml:S2:3673:1	O
and	TREANDA.xml:S2:3675:3	O
supportive	TREANDA.xml:S2:3679:10	O
care	TREANDA.xml:S2:3690:4	O
.	TREANDA.xml:S2:3694:1	O

5.4	TREANDA.xml:S2:3703:3	O
Tumor	TREANDA.xml:S2:3708:5	O
Lysis	TREANDA.xml:S2:3714:5	O
Syndrome	TREANDA.xml:S2:3720:8	O

Tumor	TREANDA.xml:S2:3734:5	B-AdverseReaction
lysis	TREANDA.xml:S2:3740:5	I-AdverseReaction
syndrome	TREANDA.xml:S2:3746:8	I-AdverseReaction
associated	TREANDA.xml:S2:3755:10	O
with	TREANDA.xml:S2:3766:4	O
TREANDA	TREANDA.xml:S2:3771:7	O
treatment	TREANDA.xml:S2:3779:9	O
has	TREANDA.xml:S2:3789:3	O
occurred	TREANDA.xml:S2:3793:8	O
in	TREANDA.xml:S2:3802:2	O
patients	TREANDA.xml:S2:3805:8	O
in	TREANDA.xml:S2:3814:2	O
clinical	TREANDA.xml:S2:3817:8	O
trials	TREANDA.xml:S2:3826:6	O
and	TREANDA.xml:S2:3833:3	O
in	TREANDA.xml:S2:3837:2	O
postmarketing	TREANDA.xml:S2:3840:13	O
reports	TREANDA.xml:S2:3854:7	O
.	TREANDA.xml:S2:3861:1	O

The	TREANDA.xml:S2:3863:3	O
onset	TREANDA.xml:S2:3867:5	O
tends	TREANDA.xml:S2:3873:5	O
to	TREANDA.xml:S2:3879:2	O
be	TREANDA.xml:S2:3882:2	O
within	TREANDA.xml:S2:3885:6	O
the	TREANDA.xml:S2:3892:3	O
first	TREANDA.xml:S2:3896:5	O
treatment	TREANDA.xml:S2:3902:9	O
cycle	TREANDA.xml:S2:3912:5	O
of	TREANDA.xml:S2:3918:2	O
TREANDA	TREANDA.xml:S2:3921:7	O
and	TREANDA.xml:S2:3929:3	O
,	TREANDA.xml:S2:3932:1	O
without	TREANDA.xml:S2:3934:7	O
intervention	TREANDA.xml:S2:3942:12	O
,	TREANDA.xml:S2:3954:1	O
may	TREANDA.xml:S2:3956:3	B-Factor
lead	TREANDA.xml:S2:3960:4	O
to	TREANDA.xml:S2:3965:2	O
acute	TREANDA.xml:S2:3968:5	B-AdverseReaction
renal	TREANDA.xml:S2:3974:5	I-AdverseReaction
failure	TREANDA.xml:S2:3980:7	I-AdverseReaction
and	TREANDA.xml:S2:3988:3	O
death	TREANDA.xml:S2:3992:5	B-AdverseReaction
.	TREANDA.xml:S2:3997:1	O

Preventive	TREANDA.xml:S2:3999:10	O
measures	TREANDA.xml:S2:4010:8	O
include	TREANDA.xml:S2:4019:7	O
vigorous	TREANDA.xml:S2:4027:8	O
hydration	TREANDA.xml:S2:4036:9	O
and	TREANDA.xml:S2:4046:3	O
close	TREANDA.xml:S2:4050:5	O
monitoring	TREANDA.xml:S2:4056:10	O
of	TREANDA.xml:S2:4067:2	O
blood	TREANDA.xml:S2:4070:5	O
chemistry	TREANDA.xml:S2:4076:9	O
,	TREANDA.xml:S2:4085:1	O
particularly	TREANDA.xml:S2:4087:12	O
potassium	TREANDA.xml:S2:4100:9	O
and	TREANDA.xml:S2:4110:3	O
uric	TREANDA.xml:S2:4114:4	O
acid	TREANDA.xml:S2:4119:4	O
levels	TREANDA.xml:S2:4124:6	O
.	TREANDA.xml:S2:4130:1	O

Allopurinol	TREANDA.xml:S2:4132:11	O
has	TREANDA.xml:S2:4144:3	O
also	TREANDA.xml:S2:4148:4	O
been	TREANDA.xml:S2:4153:4	O
used	TREANDA.xml:S2:4158:4	O
during	TREANDA.xml:S2:4163:6	O
the	TREANDA.xml:S2:4170:3	O
beginning	TREANDA.xml:S2:4174:9	O
of	TREANDA.xml:S2:4184:2	O
TREANDA	TREANDA.xml:S2:4187:7	O
therapy	TREANDA.xml:S2:4195:7	O
.	TREANDA.xml:S2:4202:1	O

However	TREANDA.xml:S2:4204:7	O
,	TREANDA.xml:S2:4211:1	O
there	TREANDA.xml:S2:4213:5	O
may	TREANDA.xml:S2:4219:3	O
be	TREANDA.xml:S2:4223:2	O
an	TREANDA.xml:S2:4226:2	O
increased	TREANDA.xml:S2:4229:9	O
risk	TREANDA.xml:S2:4239:4	B-Factor
of	TREANDA.xml:S2:4244:2	O
severe	TREANDA.xml:S2:4247:6	B-Severity
skin	TREANDA.xml:S2:4254:4	B-AdverseReaction
toxicity	TREANDA.xml:S2:4259:8	I-AdverseReaction
when	TREANDA.xml:S2:4268:4	O
TREANDA	TREANDA.xml:S2:4273:7	O
and	TREANDA.xml:S2:4281:3	O
allopurinol	TREANDA.xml:S2:4285:11	O
are	TREANDA.xml:S2:4297:3	O
administered	TREANDA.xml:S2:4301:12	O
concomitantly	TREANDA.xml:S2:4314:13	O
[	TREANDA.xml:S2:4328:1	O
see	TREANDA.xml:S2:4329:3	O
Warnings	TREANDA.xml:S2:4334:8	O
and	TREANDA.xml:S2:4343:3	O
Precautions	TREANDA.xml:S2:4347:11	O
(	TREANDA.xml:S2:4360:1	O
5.5	TREANDA.xml:S2:4363:3	O
)]	TREANDA.xml:S2:4368:2	O
.	TREANDA.xml:S2:4372:1	O

5.5	TREANDA.xml:S2:4381:3	O
Skin	TREANDA.xml:S2:4386:4	O
Reactions	TREANDA.xml:S2:4391:9	O

Skin	TREANDA.xml:S2:4406:4	B-AdverseReaction
reactions	TREANDA.xml:S2:4411:9	I-AdverseReaction
have	TREANDA.xml:S2:4421:4	O
been	TREANDA.xml:S2:4426:4	O
reported	TREANDA.xml:S2:4431:8	O
with	TREANDA.xml:S2:4440:4	O
TREANDA	TREANDA.xml:S2:4445:7	O
treatment	TREANDA.xml:S2:4453:9	O
in	TREANDA.xml:S2:4463:2	O
clinical	TREANDA.xml:S2:4466:8	O
trials	TREANDA.xml:S2:4475:6	O
and	TREANDA.xml:S2:4482:3	O
postmarketing	TREANDA.xml:S2:4486:13	O
safety	TREANDA.xml:S2:4500:6	O
reports	TREANDA.xml:S2:4507:7	O
,	TREANDA.xml:S2:4514:1	O
including	TREANDA.xml:S2:4516:9	O
rash	TREANDA.xml:S2:4526:4	B-AdverseReaction
,	TREANDA.xml:S2:4530:1	O
toxic	TREANDA.xml:S2:4532:5	B-AdverseReaction
skin	TREANDA.xml:S2:4538:4	I-AdverseReaction
reactions	TREANDA.xml:S2:4543:9	I-AdverseReaction
and	TREANDA.xml:S2:4553:3	O
bullous	TREANDA.xml:S2:4557:7	B-AdverseReaction
exanthema	TREANDA.xml:S2:4565:9	I-AdverseReaction
.	TREANDA.xml:S2:4574:1	O

Some	TREANDA.xml:S2:4576:4	O
events	TREANDA.xml:S2:4581:6	O
occurred	TREANDA.xml:S2:4588:8	O
when	TREANDA.xml:S2:4597:4	O
TREANDA	TREANDA.xml:S2:4602:7	O
was	TREANDA.xml:S2:4610:3	O
given	TREANDA.xml:S2:4614:5	O
in	TREANDA.xml:S2:4620:2	O
combination	TREANDA.xml:S2:4623:11	O
with	TREANDA.xml:S2:4635:4	O
other	TREANDA.xml:S2:4640:5	O
anticancer	TREANDA.xml:S2:4646:10	O
agents	TREANDA.xml:S2:4657:6	O
.	TREANDA.xml:S2:4663:1	O

In	TREANDA.xml:S2:4669:2	O
a	TREANDA.xml:S2:4672:1	O
study	TREANDA.xml:S2:4674:5	O
of	TREANDA.xml:S2:4680:2	O
TREANDA	TREANDA.xml:S2:4683:7	O
(	TREANDA.xml:S2:4691:1	O
90	TREANDA.xml:S2:4692:2	O
mg	TREANDA.xml:S2:4695:2	O
m	TREANDA.xml:S2:4698:1	O
2	TREANDA.xml:S2:4701:1	O
)	TREANDA.xml:S2:4704:1	O
in	TREANDA.xml:S2:4706:2	O
combination	TREANDA.xml:S2:4709:11	O
with	TREANDA.xml:S2:4721:4	O
rituximab	TREANDA.xml:S2:4726:9	O
,	TREANDA.xml:S2:4735:1	O
one	TREANDA.xml:S2:4737:3	O
case	TREANDA.xml:S2:4741:4	O
of	TREANDA.xml:S2:4746:2	O
toxic	TREANDA.xml:S2:4749:5	B-AdverseReaction
epidermal	TREANDA.xml:S2:4755:9	I-AdverseReaction
necrolysis	TREANDA.xml:S2:4765:10	I-AdverseReaction
(	TREANDA.xml:S2:4776:1	O
TEN	TREANDA.xml:S2:4777:3	B-AdverseReaction
)	TREANDA.xml:S2:4780:1	O
occurred	TREANDA.xml:S2:4782:8	O
.	TREANDA.xml:S2:4790:1	O

TEN	TREANDA.xml:S2:4792:3	O
has	TREANDA.xml:S2:4796:3	O
been	TREANDA.xml:S2:4800:4	O
reported	TREANDA.xml:S2:4805:8	O
for	TREANDA.xml:S2:4814:3	O
rituximab	TREANDA.xml:S2:4818:9	O
(	TREANDA.xml:S2:4828:1	O
see	TREANDA.xml:S2:4829:3	O
rituximab	TREANDA.xml:S2:4833:9	O
package	TREANDA.xml:S2:4843:7	O
insert	TREANDA.xml:S2:4851:6	O
)	TREANDA.xml:S2:4857:1	O
.	TREANDA.xml:S2:4858:1	O

Cases	TREANDA.xml:S2:4860:5	O
of	TREANDA.xml:S2:4866:2	O
Stevens	TREANDA.xml:S2:4869:7	B-AdverseReaction
-	TREANDA.xml:S2:4876:1	I-AdverseReaction
Johnson	TREANDA.xml:S2:4877:7	I-AdverseReaction
syndrome	TREANDA.xml:S2:4885:8	I-AdverseReaction
(	TREANDA.xml:S2:4894:1	O
SJS	TREANDA.xml:S2:4895:3	B-AdverseReaction
)	TREANDA.xml:S2:4898:1	O
and	TREANDA.xml:S2:4900:3	O
TEN	TREANDA.xml:S2:4904:3	B-AdverseReaction
,	TREANDA.xml:S2:4907:1	O
some	TREANDA.xml:S2:4909:4	O
fatal	TREANDA.xml:S2:4914:5	B-AdverseReaction
,	TREANDA.xml:S2:4919:1	O
have	TREANDA.xml:S2:4921:4	O
been	TREANDA.xml:S2:4926:4	O
reported	TREANDA.xml:S2:4931:8	O
when	TREANDA.xml:S2:4940:4	O
TREANDA	TREANDA.xml:S2:4945:7	O
was	TREANDA.xml:S2:4953:3	O
administered	TREANDA.xml:S2:4957:12	O
concomitantly	TREANDA.xml:S2:4970:13	O
with	TREANDA.xml:S2:4984:4	O
allopurinol	TREANDA.xml:S2:4989:11	O
and	TREANDA.xml:S2:5001:3	O
other	TREANDA.xml:S2:5005:5	O
medications	TREANDA.xml:S2:5011:11	O
known	TREANDA.xml:S2:5023:5	O
to	TREANDA.xml:S2:5029:2	O
cause	TREANDA.xml:S2:5032:5	O
these	TREANDA.xml:S2:5038:5	O
syndromes	TREANDA.xml:S2:5044:9	O
.	TREANDA.xml:S2:5053:1	O

The	TREANDA.xml:S2:5055:3	O
relationship	TREANDA.xml:S2:5059:12	O
to	TREANDA.xml:S2:5072:2	O
TREANDA	TREANDA.xml:S2:5075:7	O
cannot	TREANDA.xml:S2:5083:6	O
be	TREANDA.xml:S2:5090:2	O
determined	TREANDA.xml:S2:5093:10	O
.	TREANDA.xml:S2:5103:1	O

Where	TREANDA.xml:S2:5109:5	O
skin	TREANDA.xml:S2:5115:4	B-AdverseReaction
reactions	TREANDA.xml:S2:5120:9	I-AdverseReaction
occur	TREANDA.xml:S2:5130:5	O
,	TREANDA.xml:S2:5135:1	O
they	TREANDA.xml:S2:5137:4	O
may	TREANDA.xml:S2:5142:3	O
be	TREANDA.xml:S2:5146:2	O
progressive	TREANDA.xml:S2:5149:11	O
and	TREANDA.xml:S2:5161:3	O
increase	TREANDA.xml:S2:5165:8	O
in	TREANDA.xml:S2:5174:2	O
severity	TREANDA.xml:S2:5177:8	O
with	TREANDA.xml:S2:5186:4	O
further	TREANDA.xml:S2:5191:7	O
treatment	TREANDA.xml:S2:5199:9	O
.	TREANDA.xml:S2:5208:1	O

Monitor	TREANDA.xml:S2:5210:7	O
patients	TREANDA.xml:S2:5218:8	O
with	TREANDA.xml:S2:5227:4	O
skin	TREANDA.xml:S2:5232:4	O
reactions	TREANDA.xml:S2:5237:9	O
closely	TREANDA.xml:S2:5247:7	O
.	TREANDA.xml:S2:5254:1	O

If	TREANDA.xml:S2:5256:2	O
skin	TREANDA.xml:S2:5259:4	O
reactions	TREANDA.xml:S2:5264:9	O
are	TREANDA.xml:S2:5274:3	O
severe	TREANDA.xml:S2:5278:6	O
or	TREANDA.xml:S2:5285:2	O
progressive	TREANDA.xml:S2:5288:11	O
,	TREANDA.xml:S2:5299:1	O
withhold	TREANDA.xml:S2:5301:8	O
or	TREANDA.xml:S2:5310:2	O
discontinue	TREANDA.xml:S2:5313:11	O
TREANDA	TREANDA.xml:S2:5325:7	O
.	TREANDA.xml:S2:5332:1	O

5.6	TREANDA.xml:S2:5341:3	O
Other	TREANDA.xml:S2:5346:5	O
Malignancies	TREANDA.xml:S2:5352:12	O

There	TREANDA.xml:S2:5370:5	O
are	TREANDA.xml:S2:5376:3	O
reports	TREANDA.xml:S2:5380:7	O
of	TREANDA.xml:S2:5388:2	O
pre	TREANDA.xml:S2:5391:3	B-AdverseReaction
-	TREANDA.xml:S2:5394:1	I-AdverseReaction
malignant	TREANDA.xml:S2:5395:9	I-AdverseReaction
and	TREANDA.xml:S2:5405:3	O
malignant	TREANDA.xml:S2:5409:9	B-AdverseReaction
diseases	TREANDA.xml:S2:5419:8	I-AdverseReaction
that	TREANDA.xml:S2:5428:4	O
have	TREANDA.xml:S2:5433:4	O
developed	TREANDA.xml:S2:5438:9	O
in	TREANDA.xml:S2:5448:2	O
patients	TREANDA.xml:S2:5451:8	O
who	TREANDA.xml:S2:5460:3	O
have	TREANDA.xml:S2:5464:4	O
been	TREANDA.xml:S2:5469:4	O
treated	TREANDA.xml:S2:5474:7	O
with	TREANDA.xml:S2:5482:4	O
TREANDA	TREANDA.xml:S2:5487:7	O
,	TREANDA.xml:S2:5494:1	O
including	TREANDA.xml:S2:5496:9	O
myelodysplastic	TREANDA.xml:S2:5506:15	B-AdverseReaction
syndrome	TREANDA.xml:S2:5522:8	I-AdverseReaction
,	TREANDA.xml:S2:5530:1	O
myeloproliferative	TREANDA.xml:S2:5532:18	B-AdverseReaction
disorders	TREANDA.xml:S2:5551:9	I-AdverseReaction
,	TREANDA.xml:S2:5560:1	O
acute	TREANDA.xml:S2:5562:5	B-AdverseReaction
myeloid	TREANDA.xml:S2:5568:7	I-AdverseReaction
leukemia	TREANDA.xml:S2:5576:8	I-AdverseReaction
and	TREANDA.xml:S2:5585:3	O
bronchial	TREANDA.xml:S2:5589:9	B-AdverseReaction
carcinoma	TREANDA.xml:S2:5599:9	I-AdverseReaction
.	TREANDA.xml:S2:5608:1	O

The	TREANDA.xml:S2:5611:3	O
association	TREANDA.xml:S2:5615:11	O
with	TREANDA.xml:S2:5627:4	O
TREANDA	TREANDA.xml:S2:5632:7	O
therapy	TREANDA.xml:S2:5640:7	O
has	TREANDA.xml:S2:5648:3	O
not	TREANDA.xml:S2:5652:3	O
been	TREANDA.xml:S2:5656:4	O
determined	TREANDA.xml:S2:5661:10	O
.	TREANDA.xml:S2:5671:1	O

5.7	TREANDA.xml:S2:5680:3	O
Extravasation	TREANDA.xml:S2:5685:13	O
Injury	TREANDA.xml:S2:5699:6	O

TREANDA	TREANDA.xml:S2:5711:7	O
extravasations	TREANDA.xml:S2:5719:14	B-AdverseReaction
have	TREANDA.xml:S2:5734:4	O
been	TREANDA.xml:S2:5739:4	O
reported	TREANDA.xml:S2:5744:8	O
in	TREANDA.xml:S2:5753:2	O
post	TREANDA.xml:S2:5756:4	O
marketing	TREANDA.xml:S2:5761:9	O
resulting	TREANDA.xml:S2:5771:9	O
in	TREANDA.xml:S2:5781:2	O
hospitalizations	TREANDA.xml:S2:5784:16	O
from	TREANDA.xml:S2:5801:4	O
erythema	TREANDA.xml:S2:5806:8	B-AdverseReaction
,	TREANDA.xml:S2:5814:1	O
marked	TREANDA.xml:S2:5816:6	B-Severity
swelling	TREANDA.xml:S2:5823:8	B-AdverseReaction
,	TREANDA.xml:S2:5831:1	O
and	TREANDA.xml:S2:5833:3	O
pain	TREANDA.xml:S2:5837:4	B-AdverseReaction
.	TREANDA.xml:S2:5841:1	O

Assure	TREANDA.xml:S2:5843:6	O
good	TREANDA.xml:S2:5850:4	O
venous	TREANDA.xml:S2:5855:6	O
access	TREANDA.xml:S2:5862:6	O
prior	TREANDA.xml:S2:5869:5	O
to	TREANDA.xml:S2:5875:2	O
starting	TREANDA.xml:S2:5878:8	O
TREANDA	TREANDA.xml:S2:5887:7	O
infusion	TREANDA.xml:S2:5895:8	O
and	TREANDA.xml:S2:5904:3	O
monitor	TREANDA.xml:S2:5908:7	O
the	TREANDA.xml:S2:5916:3	O
intravenous	TREANDA.xml:S2:5920:11	O
infusion	TREANDA.xml:S2:5932:8	O
site	TREANDA.xml:S2:5941:4	O
for	TREANDA.xml:S2:5946:3	O
redness	TREANDA.xml:S2:5950:7	O
,	TREANDA.xml:S2:5957:1	O
swelling	TREANDA.xml:S2:5959:8	O
,	TREANDA.xml:S2:5967:1	O
pain	TREANDA.xml:S2:5969:4	O
,	TREANDA.xml:S2:5973:1	O
infection	TREANDA.xml:S2:5975:9	O
,	TREANDA.xml:S2:5984:1	O
and	TREANDA.xml:S2:5986:3	O
necrosis	TREANDA.xml:S2:5990:8	O
during	TREANDA.xml:S2:5999:6	O
and	TREANDA.xml:S2:6006:3	O
after	TREANDA.xml:S2:6010:5	O
administration	TREANDA.xml:S2:6016:14	O
of	TREANDA.xml:S2:6031:2	O
TREANDA	TREANDA.xml:S2:6034:7	O
.	TREANDA.xml:S2:6041:1	O

5.8	TREANDA.xml:S2:6050:3	O
Embryo	TREANDA.xml:S2:6055:6	O
-	TREANDA.xml:S2:6061:1	O
fetal	TREANDA.xml:S2:6062:5	O
Toxicity	TREANDA.xml:S2:6068:8	O

TREANDA	TREANDA.xml:S2:6082:7	O
can	TREANDA.xml:S2:6090:3	B-Factor
cause	TREANDA.xml:S2:6094:5	O
fetal	TREANDA.xml:S2:6100:5	B-AdverseReaction
harm	TREANDA.xml:S2:6106:4	I-AdverseReaction
when	TREANDA.xml:S2:6111:4	O
administered	TREANDA.xml:S2:6116:12	O
to	TREANDA.xml:S2:6129:2	O
a	TREANDA.xml:S2:6132:1	O
pregnant	TREANDA.xml:S2:6134:8	O
woman	TREANDA.xml:S2:6143:5	O
.	TREANDA.xml:S2:6148:1	O

Single	TREANDA.xml:S2:6151:6	O
intraperitoneal	TREANDA.xml:S2:6158:15	O
doses	TREANDA.xml:S2:6174:5	O
of	TREANDA.xml:S2:6180:2	O
bendamustine	TREANDA.xml:S2:6183:12	O
in	TREANDA.xml:S2:6196:2	O
mice	TREANDA.xml:S2:6199:4	B-Animal
and	TREANDA.xml:S2:6204:3	O
rats	TREANDA.xml:S2:6208:4	B-Animal
administered	TREANDA.xml:S2:6213:12	O
during	TREANDA.xml:S2:6226:6	O
organogenesis	TREANDA.xml:S2:6233:13	O
caused	TREANDA.xml:S2:6247:6	O
an	TREANDA.xml:S2:6254:2	O
increase	TREANDA.xml:S2:6257:8	B-AdverseReaction
in	TREANDA.xml:S2:6266:2	I-AdverseReaction
resorptions	TREANDA.xml:S2:6269:11	I-AdverseReaction
,	TREANDA.xml:S2:6280:1	O
skeletal	TREANDA.xml:S2:6282:8	B-AdverseReaction
and	TREANDA.xml:S2:6291:3	O
visceral	TREANDA.xml:S2:6295:8	B-AdverseReaction
malformations	TREANDA.xml:S2:6304:13	I-AdverseReaction
,	TREANDA.xml:S2:6317:1	O
and	TREANDA.xml:S2:6319:3	O
decreased	TREANDA.xml:S2:6323:9	B-AdverseReaction
fetal	TREANDA.xml:S2:6333:5	I-AdverseReaction
body	TREANDA.xml:S2:6339:4	I-AdverseReaction
weights	TREANDA.xml:S2:6344:7	I-AdverseReaction
.	TREANDA.xml:S2:6351:1	O

[	TREANDA.xml:S2:6353:1	O
see	TREANDA.xml:S2:6354:3	O
Use	TREANDA.xml:S2:6359:3	O
in	TREANDA.xml:S2:6363:2	O
Specific	TREANDA.xml:S2:6366:8	O
Populations	TREANDA.xml:S2:6375:11	O
(	TREANDA.xml:S2:6388:1	O
8.1	TREANDA.xml:S2:6391:3	O
)]	TREANDA.xml:S2:6396:2	O
